Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Chemopreventive Agent Development Research Group

Publications

View All  |  2014-2010  |  2009-2000  |  1999-1990  |  1989-1985

2014

  • Pepper JW, Dunn BK, Fagerstrom RM, Gohagan JK, Vydelingum NA. Using systems biology to understand cancer as an evolutionary process.Exit Disclaimer Journal of Evolutionary Medicine. 2014 (2)1-8.
  • Ravillah D, Mohammed A, Qian L, Brewer M, Zhang Y, Biddick L, Steele VE, Rao CV. Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. J Pharmacol Exp Ther. 2014 Jan;348(1):59-68. Epub 2013 Nov 11.
    [ PubMed Abstract ]

2013

  • Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL, Jr. Bowman Birk Inhibitor Concentrate and oral leukoplakia: A randomized phase IIb trial. Cancer Prev Res (Phila) 6:410-18, 2013.
    [ PubMed Abstract ]
  • Banerjee AA, Shen H, Hautman M, Anwer J, Hong S, Kapetanovic IM, Lyubimov AV, Liu Y. Polymeric nanoparticles enhance the bioavailability of the chemopreventive agent SR13668 in beagle dogs. Curr Pharm Biotechnol Apr 11: Epub ahead of print, 2013.
    [ PubMed Abstract ]
  • Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol 53:403-12, 2013.
    [ PubMed Abstract ]
  • Bhardwaj P, Du B, Zhou XK, Sue E, Harbus MD, Falcone DJ, Giri D, Hudis CA, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Caloric restriction reverses obesity-induced mammary gland inflammation in mice. Cancer Prev Res (Phila) 6:282-89, 2013.
    [ PubMed Abstract ]
  • Chaudhary SC, Singh T, Kapur P, Weng Z, Arumugam A, Elmets CA, Kopelovich L, Athar M. Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis. Toxicol Appl Pharmacol 268:49-255, 2013.
    [ PubMed Abstract ]
  • Dragnev K, You M, Wang Y, Lubet R. Lung cancer chemoprevention: Difficulties, promise and potential agents? Expert Opin Investig Drugs 22:35-47, 2013.
    [ PubMed Abstract ]
  • Dunn BK, Cazzaniga M, DeCensi A. Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer. Breast 22:225-37, 2013.
    [ PubMed Abstract ]
  • Fagan RL, Cryderman DE, Kopelovich L, Wallrath LL, Brenner C. Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1. J Biol Chem Jul 9: Epub ahead of print, 2013.
    [ PubMed Abstract ]
  • Fan M, Pfeffer SR, Lynch HT, Cassidy P, Leachman S, Pfeffer LM, Kopelovich L. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: Relevance to early intervention. Oncotarget 4: 128-41, 2013.
    [ PubMed Abstract ]
  • Izzotti A, Balansky R, D'Agostini F, Longobardi M, Cartiglia C, La Maestra S, Micale RT, Camoirano A, Ganchev G, Iltcheva M, Steele VE, De Flora S. Relationships between pulmonary micro-RNA and proteome profiles, systemic cytogenetic damage and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents. Carcinogenesis. 2013 Oct;34(10):2322-9. Epub 2013 May 24.
    [ PubMed Abstract ]
  • Janakiram NB, Mohammed A, Zhang Y, Brewer M, Bryant T, Lightfoot S, Steele VE, Rao CV. Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev Res (Phila). 2013 Dec;6(12):1251-61. Epub 2013 Sep 30.
    [ PubMed Abstract ]
  • Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, Martin-Jimenez T, Onua E, Banerjee A, van Breemen RB, Nikolic D, Chen L, Lyubimov AV. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol 36:284-95, 2013.
    [ PubMed Abstract ]
  • Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, Pressey JG, Athar M. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model. Biochem Biophys Res Commun 435:557-61, 2013.
    [ PubMed Abstract ]
  • Kurundkar D, Srivastava RK, Chaudhary SC, Ballestas ME, Kopelovich L, Elmets CA, Athar M. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 266:233-44, 2013.
    [ PubMed Abstract ]
  • La Maestra S, Micale RT, De Flora S, D'Agostini F, Ganchev G, Iltcheva M, Petkov N, Steele VE, Balansky R. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis. 2013 Jan;34(1):183-9. Epub 2012 Oct 5.
    [ PubMed Abstract ]
  • Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, D'Alessio A, Normanno N, Dong Z, Bode AM. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G2/M arrest and apoptosis. Mol Carcinog 52:134-43, 2013.
    [ PubMed Abstract ]
  • Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ. Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis. Cancer Prev Res (Phila). 2013 May;6(5):448-54. Epub 2013 Mar 26.
    [ PubMed Abstract ]
  • Mehta RG, Peng X, Roy S, Hawthorne M, Kalra A, Alimirah F, Mehta RR, Kopelovich L. PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: Potential translational significance. Mol Cell Biochem 372:249-56, 2013.
    [ PubMed Abstract ]
  • Micale RT, La Maestra S, Di Pietro A, Visalli G, Baluce B, Balansky R, Steele VE, De Flora S. Oxidative stress in the lung of mice exposed to cigarette smoke either early in life or in adulthood. Arch Toxicol. 2013 May;87(5):915-8. Epub 2013 Feb 20. Erratum in: Arch Toxicol. 2013 May;87(5):919. Maestra, Sebastiano La [corrected to La Maestra, Sebastiano]; Pietro, Angela Di.
    [ PubMed Abstract ]
  • Mikulec CD, Rundhaug JE, Simper MS, Lubet RA, Fischer SM. The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: The relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prev Res (Phila) 6:675-85, 2013.
    [ PubMed Abstract ]
  • Mohammed A, Janakiram NB, Brewer M, Vedala K, Steele VE, Rao CV. Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis. Neoplasia. 2013 May;15(5):481-90.
    [ PubMed Abstract ]
  • Nicastro HL, Dunn BK. Selenium and prostate cancer prevention: Insights from the selenium and vitamin E cancer prevention trial (SELECT). Nutrients 5:1122-48, 2013.
    [ PubMed Abstract ]
  • Nicastro HL, Grubbs CJ, Juliana MM, Bode AM, Kim MS, Lu Y, You M, Milne G, Boring D, Steele VE, Lubet RA. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer Prev Res (Phila). 2013 Dec 17. [Epub ahead of print]
    [ PubMed Abstract ]
  • Pepper JA, Vydelingum NA, Dunn BK, Fagerstrom RM. Agent-based models in cancer prevention. In: Kora AB, editor. Advances in Computational Modeling Research: Theory, Developments and Applications. Hauppauge, NY: Nova Science Publishers, 2013, p.105-16.
  • Perloff M, Steele VE. Early-phase development of cancer prevention agents: challenges and opportunities. Cancer Prev Res (Phila). 2013 May;6(5):379-83. Epub 2013 Mar 6.
    [ PubMed Abstract ]
  • Rao CV, Patlolla JM, Cooma I, Kawamori T, Steele VE. Prevention of familial adenomatous polyp development in APC min mice and azoxymethane-induced colon carcinogenesis in F344 Rats by ?-3 fatty acid rich perilla oil. Nutr Cancer. 2013;65 Suppl 1:54-60.
    [ PubMed Abstract ]
  • Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4 methyl-UAB30, and Targretin (bexarotene). Mol Pharmacol 83:698-708, 2013.
    [ PubMed Abstract ]
  • Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, You M. Chemopreventive effect of a mixture of Chinese herbs (antitumor B) on chemically induced oral carcinogenesis. Mol Carcinog 52:49-56, 2013.
    [ PubMed Abstract ]
  • Witherspoon M, Chen Q, Kopelovich L, Gross SS, Lipkin SM. Unbiased metabolite profiling indicates that a diminished thymidine pools is the underlying mechanism of colon cancer chemoprevention by a-difluoromethylornithine (DFMO). Cancer Discov Jun 14: Epub ahead of print, 2013.
    [ PubMed Abstract ]
  • Xie H, Lee MH, Zhu F, Reddy K, Huang Z, Kim DJ, Li Y, Peng C, Lim do Y, Kang S, Jung SK, Li X, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z. Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo. Mol Cancer Ther 12:950-58, 2013.
    [ PubMed Abstract ]
  • Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim do Y, Kim DJ, Li X, Kang S, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res 73:716-24, 2013.
    [ PubMed Abstract ]
  • Yuan H, Lu J, Xiao J, Upadhyay G, Umans R, Kallakury B, Yin Y, Fant ME, Kopelovich L, Glazer RI. PPARd induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation. Cancer Res Jun 27: Epub ahead of print, 2013.
    [ PubMed Abstract ]

2012

  • Balansky R, D'Agostini F, Micale RT, La Maestra S, Steele VE, De Flora S. Dose-related cytogenetic damage in pulmonary alveolar macrophages from mice exposed to cigarette smoke early in life. Arch Toxicol 86:509-16, 2012.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Kratchanova M, Denev P, Kratchanov C, Polasa K, D'Agostini F, Steele VE, De Flora S. Inhibition of lung tumor development by berry extracts in mice exposed to cigarette smoke. Int J Cancer 131:1991-97, 2012.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Nikolov M, Steele VE, De Flora S. Differential carcinogenicity of cigarette smoke in mice exposed either transplacentally, early in life or in adulthood. Int J Cancer 130:1001-10, 2012.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Transplacental antioxidants inhibit lung tumors in mice exposed to cigarette smoke after birth: A novel preventative strategy? Curr Cancer Drug Targets 12:164-69, 2012.
    [ PubMed Abstract ]
  • Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem Pharmacol 83:723-32, 2012.
    [ PubMed Abstract ]
  • Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem Pharmacol 83:715-22, 2012.
    [ PubMed Abstract ]
  • Chattopadhyay M, Kodela R, Nath N, Street CR, Velazquez-Martinez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol 83:733-40, 2012.
    [ PubMed Abstract ]
  • Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 88:1149-56, 2012.
    [ PubMed Abstract ]
  • Chen H, Yao K, Nadas J, Bode AM, Malakhova M, Oi N, Li H, Lubet RA, Dong Z. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One 7: e38261, 2012.
    [ PubMed Abstract ]
  • Crous-Bou M, Rennert G, Salazar R, Rodriguez-Moranta F, Rennert HS, Lejbkowicz F, Kopelovich L, Lipkin SM, Gruber SB, Moreno V. Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer. Mutagenesis 27:169-76, 2012.
    [ PubMed Abstract ]
  • De Flora S, Balansky R, D'Agostini F, Cartiglia C, Longobardi M, Steele VE, Izzotti A. Smoke-induced microRNA and related proteome alterations. Modulation by chemopreventive agents. Int J Cancer 131:2763-73, 2012.
    [ PubMed Abstract ]
  • Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG. Exemestane for breast cancer prevention: A critical shift? Cancer Discov 2:25-40, 2012.
    [ PubMed Abstract ]
  • Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res 746:78-88, 2012.
    [ PubMed Abstract ]
  • Dunn BK, Akpa E. Biomarkers as surrogate endpoints in cancer trials. Semin Oncol Nurs 28:99-108, 2012.
    [ PubMed Abstract ]
  • Izzotti A, Cartiglia C, Steele VE, De Flora S. MicroRNAs as targets for dietary and pharmaco-logical inhibitors of mutagenesis and carcinogenesis. Mutat Res 751:287-303, 2012.
    [ PubMed Abstract ]
  • Janakiram NB, Mohammed A, Qian L, Choi CI, Steele VE, Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of ApcMin/+ mice. Neoplasia 14:159-68, 2012.
    [ PubMed Abstract ]
  • Kapetanovic IM. Comment on 'Resveratrol in human cancer chemoprevention--choosing the 'right' dose'. Mol Nutr Food Res 56:523, 2012.
    [ PubMed Abstract ]
  • Kapetanovic IM, Lyubimov AV, Kabirova EV, Kabirov KK, Rasay L, Swezey R, Green C, Kopelovich L. Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailability. Chem Biol Interact 197:16-22, 2012.
    [ PubMed Abstract ]
  • Kapetanovic IM, Muzzio M, McCormick DL, Thompson TN, Johnson WD, Horn TL, Mohammed A, Rao CV, Kopelovich L. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. Cancer Chemother Pharmacol 69:1301-06, 2012.
    [ PubMed Abstract ]
  • Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A. Oral low dose and topical tamoxifen for breast cancer prevention: Modern approaches for an old drug. Breast Cancer Res 14:214, 2012.
    [ PubMed Abstract ]
  • Li X, Li H, Li S, Zhu F, Kim DJ, Xie H, Li Y, Nadas J, Oi N, Zykova TA, Yu DH, Lee MH, Kim MO, Wang L, Ma W, Lubet RA, Bode AM, Dong Z, Dong Z. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis 33:2548-57, 2012.
    [ PubMed Abstract ]
  • Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res (Phila) 5:248-59, 2012.
    [ PubMed Abstract ]
  • Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep 27:1400-06, 2012.
    [ PubMed Abstract ]
  • Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer 131:1951-62, 2012.
    [ PubMed Abstract ]
  • Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K, Dannenberg AJ. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) 5:1358-67, 2012.
    [ PubMed Abstract ]
  • Muzzio M, Huang Z, Hu SC, Johnson WD, McCormick DL, Kapetanovic IM. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal 59:201-08, 2012.
    [ PubMed Abstract ]
  • Oi N, Chen H, Ok Kim M, Lubet RA, Bode AM, Dong Z. Taxifolin suppresses UV-induced skin carcinogenesis by targeting EGFR and PI3K. Cancer Prev Res (Phila) 5:1103-14, 2012.
    [ PubMed Abstract ]
  • Patlolla JM, Zhang Y, Li Q, Steele VE, Rao CV. Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol 40:170-75, 2012.
    [ PubMed Abstract ]
  • Pereira MA, Warner BM, Knobloch TJ, Weghorst CM, Lubet RA, Steele VE, Casto BC. Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin. Int J Cancer 131:1277-86, 2012.
    [ PubMed Abstract ]
  • Rao CV, Mohammed A, Janakiram NB, Li Q, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48Cre/+-LSL-KrasG12D/+ mice. Neoplasia 14:778-87, 2012.
    [ PubMed Abstract ]
  • Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41-46, 2012.
    [ PubMed Abstract ]
  • Roman-Perez E, Casbas-Hernandez P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14:R51, 2012.
    [ PubMed Abstract ]
  • Shen H, Banerjee AA, Mlynarska P, Hautman M, Hong S, Kapetanovic IM, Lyubimov AV, Liu Y. Enhanced oral bioavailability of a cancer preventive agent (SR13668) by employing polymeric nanoparticles with high drug loading. J Pharm Sci 101:3877-85, 2012.
    [ PubMed Abstract ]
  • Singh T, Chaudhary SC, Kapur P, Weng Z, Elmets CA, Kopelovich L, Athar M. Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis. Photochem Photobiol 88:1141-48, 2012.
    [ PubMed Abstract ]
  • Smith JJ, Dunn BK. Biomarkers as molecular targets of drug interventions. Semin Oncol Nurs 28:109-15, 2012.
    [ PubMed Abstract ]
  • Smith JJ, Dunn BK. Introduction. Semin Oncol Nurs 28:85-86, 2012.
    [ PubMed Abstract ]
  • Subbaramaiah K, Howe LR, Zhou XK, Yang P, Hudis CA, Kopelovich L, Dannenberg AJ. Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: Evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res (Phila) 5:1183-94, 2012.
    [ PubMed Abstract ]
  • Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2:356-65, 2012.
    [ PubMed Abstract ]
  • Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer 12:835-48, 2012.
    [ PubMed Abstract ]
  • Wang Y, Rouggly L, You M, Lubet R. Animal models of lung cancer characterization and use for chemoprevention research. Prog Mol Biol Transl Sci 105:211-26, 2012.
    [ PubMed Abstract ]
  • Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol 165:2152-66, 2012.
    [ PubMed Abstract ]
  • Xie H, Zhu F, Huang Z, Lee MH, Kim DJ, Li X, Lim do Y, Jung SK, Kang S, Li H, Reddy K, Wang L, Ma W, Lubet RA, Bode AM, Dong Z. Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis 33:1814-21, 2012.
    [ PubMed Abstract ]
  • Yuan H, Kopelovich L, Yin Y, Lu J, Glazer RI. Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget 3:345-56, 2012.
    [ PubMed Abstract ]
  • Yuan H, Upadhyay G, Lu J, Kopelovich L, Glazer RI. The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature. Cancer Prev Res (Phila) 5:754-64, 2012.
    [ PubMed Abstract ]
  • Yuan H, Upadhyay G, Yin Y, Kopelovich L, Glazer RI. Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation. Cancer Prev Res (Phila) 5:51-60, 2012.
    [ PubMed Abstract ]
  • Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, You M. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res (Phila) 5:717-25, 2012.
    [ PubMed Abstract ]
  • Zhang Q, Pan J, Wang Y, Lubet R, You M. Beetroot red (betanin) inhibits vinyl carbamate- and benzo(a)pyrene-induced lung tumorigenesis through apoptosis. Mol Carcinog 2012;52:686-91.
    [ PubMed Abstract ]

2011

  • Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 17:631-39, 2011.
    [ PubMed Abstract ]
  • Athar M, Kopelovich L. Rapamycin and mTORC1 inhibition in the mouse: Skin cancer prevention. Cancer Prev Res (Phila) 4:957-61, 2011.
    [ PubMed Abstract ]
  • Athar M, Walsh SB, Kopelovich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys 508:159-63, 2011.
    [ PubMed Abstract ]
  • Bishayee A, Ahmed S, Brankov N, Perloff M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 16:980-96, 2011.
    [ PubMed Abstract ]
  • Dunn BK, Jegalian K, Greenwald P. Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: Issues and opportunities. Recent Results Cancer Res 188:21-47, 2011.
    [ PubMed Abstract ]
  • Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4:1728-35, 2011.
    [ PubMed Abstract ]
  • Fu H, Zhang J, Pan J, Zhang Q, Lu Y, Wen W, Lubet RA, Szabo E, Chen R, Wang Y, Chen DR, You M. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. Mol Carcinog 50:913-21, 2011.
    [ PubMed Abstract ]
  • Green CE, Swezey R, Bakke J, Shinn W, Furimsky A, Bejugam N, Shankar GN, Jong L, Kapetanovic IM. Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent. Cancer Chemother Pharmacol 67:995-1006, 2011.
    [ PubMed Abstract ]
  • Izzotti A, Larghero P, Balansky R, Pfeffer U, Steele VE, De Flora S. Interplay between histopathological alterations, cigarette smoke and chemopreventive agents in defining microRNA profiles in mouse lung. Mutat Res 717:17-24, 2011.
    [ PubMed Abstract ]
  • Izzotti A, Larghero P, Longobardi M, Cartiglia C, Camoirano A, Steele VE, De Flora S. Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. Mutat Res 717:9-16, 2011.
    [ PubMed Abstract ]
  • Johnson WD, Morrissey RL, Usborne AL, Kapetanovic I, Crowell JA, Muzzio M, McCormick DL. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol 49:3319-27, 2011.
    [ PubMed Abstract ]
  • Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L, McCormick DL. Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology 289:141-50, 2011.
    [ PubMed Abstract ]
  • Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68:593-601, 2011.
    [ PubMed Abstract ]
  • Kim DJ, Reddy K, Kim MO, Li Y, Nadas J, Cho YY, Kim JE, Shim JH, Song NR, Carper A, Lubet RA, Bode AM, Dong Z. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila) 4:1842-51, 2011.
    [ PubMed Abstract ]
  • Kim KH, Back JH, Zhu Y, Arbesman J, Athar M, Kopelovich L, Kim AL, Bickers DR. Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression. J Invest Dermatol 131:195-202, 2011.
    [ PubMed Abstract ]
  • Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, Kashfi K. Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents. Bioorg Med Chem Lett 21:7146-50, 2011.
    [ PubMed Abstract ]
  • La Maestra S, Kisby GE, Micale RT, Johnson J, Kow YW, Bao G, Sheppard C, Stanfield S, Tran H, Woltjer RL, D'Agostini F, Steele VE, De Flora S. Cigarette smoke induces DNA damage and alters base-excision repair and tau levels in the brain of neonatal mice. Toxicol Sci 123:471-79, 2011.
    [ PubMed Abstract ]
  • Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, Ericson ME, Bode AM. Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways. Cancer Prev Res (Phila) 4:1190-97, 2011.
    [ PubMed Abstract ]
  • Li Y, Kim DJ, Ma W, Lubet RA, Bode AM, Dong Z. Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures. J Chem Inf Model 51:2904-14, 2011.
    [ PubMed Abstract ]
  • Lindeblad M, Kapetanovic IM, Kabirov KK, Dinger N, Mankovskaya I, Morrisey R, Martin-Jimenez T, Lyubimov A. Assessment of oral toxicity and safety of 9-cis-UAB30, a potential chemopreventive agent, in rat and dog studies. Drug Chem Toxicol 34:300-10, 2011.
    [ PubMed Abstract ]
  • Lubet RA, Heckman BM, De Flora SL, Steele VE, Crowell JA, Juliana MM, Grubbs CJ. Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: Is DIM a substitute for I3C? Oncol Rep 26:731-36, 2011.
    [ PubMed Abstract ]
  • Lubet RA, Lu Y, Bode AM, You M, Verney ZM, Steele VE, Townsend R, Juliana MM, Grubbs CJ. Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers. Oncol Rep 25:1389-97, 2011.
    [ PubMed Abstract ]
  • Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 4:1052-60, 2011.
    [ PubMed Abstract ]
  • Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 4:1938-44, 2011.
    [ PubMed Abstract ]
  • McIlhatton MA, Tyler J, Kerepesi LA, Bocker-Edmonston T, Kucherlapati MH, Edelmann W, Kucherlapati R, Kopelovich L, Fishel R. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res (Phila) 4:684-93, 2011.
    [ PubMed Abstract ]
  • Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APCMin/+ mice by licofelone, a novel dual 5 LOX/COX inhibitor: Potential implications for human colon cancer prevention. Cancer Prev Res (Phila) 4:2015-26, 2011.
    [ PubMed Abstract ]
  • Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4:1021-29, 2011.
    [ PubMed Abstract ]
  • Muzzio M, Huang Z, Johnson WD, McCormick DL, Kapetanovic IM. Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS. J Pharm Biomed Anal 56:809-14, 2011.
    [ PubMed Abstract ]
  • Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Gynecol Oncol 120:474-79, 2011.
    [ PubMed Abstract ]
  • Parman T, Bunin DI, Ng HH, McDunn JE, Wulff JE, Wang A, Swezey R, Rasay L, Fairchild DG, Kapetanovic IM, Green CE. Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. Toxicol Sci 124:487-501, 2011.
    [ PubMed Abstract ]
  • Patel BB, Li XM, Dixon MP, Blagoi EL, Nicolas E, Seeholzer SH, Cheng D, He YA, Coudry RA, Howard SD, Riddle DM, Cooper HC, Boman BM, Conrad P, Crowell JA, Bellacosa A, Knudson A, Yeung AT, Kopelovich L. APC+/- alters colonic fibroblast proteome in FAP. Oncotarget 2:197-208, 2011.
    [ PubMed Abstract ]
  • Pollock CB, Yin Y, Yuan H, Zeng X, King S, Li X, Kopelovich L, Albanese C, Glazer RI. PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis. PLoS One 6:e16215, 2011.
    [ PubMed Abstract ]
  • Protiva P, Mason JB, Liu Z, Hopkins ME, Nelson C, Marshall JR, Lambrecht RW, Pendyala S, Kopelovich L, Kim M, Kleinstein SH, Laird PW, Lipkin M, Holt PR. Altered folate availability modifies the molecular environment of the human colorectum: Implications for colorectal carcinogenesis. Cancer Prev Res (Phila) 4:530-43, 2011.
    [ PubMed Abstract ]
  • Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) 4:347-53, 2011.
    [ PubMed Abstract ]
  • Scaglioni PP, Cai LF, Majid SM, Yung TM, Socci ND, Kogan SC, Kopelovich L, Pandolfi PP. Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model. Genes Cancer 2:160-65, 2011.
    [ PubMed Abstract ]
  • Sharma S, Lee J, Gao P, Steele VE. Toxicity profile of solvents by aspiration approach for topical agent delivery to respiratory tract epithelium. Int J Toxicol 30:358-66, 2011.
    [ PubMed Abstract ]
  • Sharma S, Lee J, Zhou J, Steele VE. Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration. Cancer Prev Res (Phila) 4:1233-42, 2011.
    [ PubMed Abstract ]
  • Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4:329-46, 2011.
    [ PubMed Abstract ]
  • Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, Grizzle WE, Timares L, Huang CC, Kopelovich L, Elmets CA, Athar M. Cyclosporine A mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: Role of TGFβ signaling pathway. Mol Carcinog 50:516-27, 2011.
    [ PubMed Abstract ]
  • Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, Maitra A, Matthaei H, Eshleman JR, Hruban RH, Kinzler KW, Pandey A, Vogelstein B. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 108:2444-49, 2011.
    [ PubMed Abstract ]
  • Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B. Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action. Exp Cell Res 317:1359-67, 2011.
    [ PubMed Abstract ]
  • Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA, Jr., Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108:21188-93, 2011.
    [ PubMed Abstract ]
  • Wu KM, Yao J, Boring D. Green tea extract-induced lethal toxicity in fasted but not in nonfasted dogs. Int J Toxicol 30:19-20, 2011.
    [ PubMed Abstract ]
  • Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: Efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337:876-86, 2011.
    [ PubMed Abstract ]
  • Xu J, Walsh SB, Verney ZM, Kopelovich L, Elmets CA, Athar M. Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway. Biochem Biophys Res Commun 408:363-68, 2011.
    [ PubMed Abstract ]
  • Zhang Q, Pan J, Zhang J, Liu P, Chen R, Chen DR, Lubet R, Wang Y, You M. Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice. Cancer Prev Res (Phila) 4:270-76, 2011.
    [ PubMed Abstract ]

2010

  • Agurs-Collins T, Dunn BK, Browne D, Johnson KA, Lubet R. Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. Semin Oncol 37:384-401, 2010.
    [ PubMed Abstract ]
  • Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: Large and small trials. Semin Oncol 37:367-83, 2010.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer 126:1047-54, 2010.
    [ PubMed Abstract ]
  • Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) 3:48-61, 2010.
    [ PubMed Abstract ]
  • Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003-11, 2010.
    [ PubMed Abstract ]
  • Calzone K, Wattendorf D, Dunn BK. The application of genetics and genomics to cancer prevention. Semin Oncol 37:407-18, 2010.
    [ PubMed Abstract ]
  • Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation. Cancer Lett 298:204-11, 2010.
    [ PubMed Abstract ]
  • Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168-75, 2010.
    [ PubMed Abstract ]
  • Cwik MJ, Wu H, Muzzio M, McCormick DL, Kapetanovic I. Direct quantitation of glucoraphanin in dog and rat plasma by LC-MS/MS. J Pharm Biomed Anal 52:544-49, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: Biology meets socioeconomic status. Breast Cancer Res Treat 121:281-92, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, Tang G, Kazerouni N, Rosenberg PS, Meerzaman DM, Buetow KH. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. Int J Mol Epidemiol Genet 1:332-49, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Greenwald P. Cancer Prevention II: Introduction. Semin Oncol 37:321-26, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Greenwald P. Cancer prevention I: Introduction. Semin Oncol 37:190-201, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer 62:896-918, 2010.
    [ PubMed Abstract ]
  • Dunn BK, Wagner PD, Anderson D, Greenwald P. Molecular markers for early detection. Semin Oncol 37:224-42, 2010.
    [ PubMed Abstract ]
  • Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, Edenberg HJ, Pennington RE, Lipkin SM, Kopelovich L. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 1:405-22, 2010.
    [ PubMed Abstract ]
  • Herschkowitz JI, Lubet R. Mouse models of triple negative [basal-like/claudin low breast cancer. Breast Dis 32:63-71, 2010.
    [ PubMed Abstract ]
  • Izzotti A, Calin GA, Steele VE, Cartiglia C, Longobardi M, Croce CM, De Flora S. Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. Cancer Prev Res (Phila) 3:62-72, 2010.
    [ PubMed Abstract ]
  • Izzotti A, Larghero P, Cartiglia C, Longobardi M, Pfeffer U, Steele VE, De Flora S. Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung. Carcinogenesis 31:894-901, 2010.
    [ PubMed Abstract ]
  • Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, Collin P, Steele VE, Rao CV. Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth. Cancer Prev Res (Phila) 3:82-91, 2010.
    [ PubMed Abstract ]
  • Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 5:e9201, 2010.
    [ PubMed Abstract ]
  • Kapetanovic IM, Horn TL, Johnson WD, Cwik MJ, Detrisac CJ, McCormick DL. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention. Int J Toxicol 29:157-64, 2010.
    [ PubMed Abstract ]
  • Kapetanovic IM, Muzzio M, Hu SC, Crowell JA, Rajewski RA, Haslam JL, Jong L, McCormick DL. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemother Pharmacol 65:1109-16, 2010.
    [ PubMed Abstract ]
  • Lee KM, Lee KW, Jung SK, Lee EJ, Heo YS, Bode AM, Lubet RA, Lee HJ, Dong Z. Kaempferol inhibits UVB-induced COX-2 expression by suppressing Src kinase activity. Biochem Pharmacol 80:2042-49, 2010.
    [ PubMed Abstract ]
  • Lindeblad M, Kapetanovic IM, Kabirov KK, Detrisac CJ, Dinger N, Mankovskaya I, Zakharov A, Lyubimov AV. Assessment of oral toxicity and safety of pentamethylchromanol (PMCol), a potential chemopreventative agent, in rats and dogs. Toxicology 273:19-28, 2010.
    [ PubMed Abstract ]
  • Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF, Schwartz A, Kapetanovic IM, Lyubimov A. Pharmacokinetic and tissue distribution study of [14C] fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact 183:317-26, 2010.
    [ PubMed Abstract ]
  • Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 3:597-603, 2010.
    [ PubMed Abstract ]
  • Lu Y, Liu P, Wen W, Grubbs CJ, Townsend RR, Malone JP, Lubet RA, You M. Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res 3:8-27, 2010.
    [ PubMed Abstract ]
  • Lubet RA, Steele VE, Juliana MM, Grubbs CJ. Screening agents for preventive efficacy in a bladder cancer model: Study design, end points, and gefitinib and naproxen efficacy. J Urol 183:1598-1603, 2010.
    [ PubMed Abstract ]
  • Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139:1320-32, 2010.
    [ PubMed Abstract ]
  • McCormick DL, Phillips JM, Horn TL, Johnson WD, Steele VE, Lubet RA. Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors. Cancer Prev Res (Phila) 3:73-81, 2010.
    [ PubMed Abstract ]
  • McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE. Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila) 3:381-92, 2010.
    [ PubMed Abstract ]
  • Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV. The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila) 3:1417-26, 2010.
    [ PubMed Abstract ]
  • Nath N, Chattopadhyay M, Kodela R, Tian S, Vlismas P, Boring D, Crowell JA, Kashfi K. Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells. Biochem Pharmacol 79:1759-71, 2010.
    [ PubMed Abstract ]
  • Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392-99, 2010.
    [ PubMed Abstract ]
  • Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, Glazer RI. Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation. PPAR Res 2010:571783, 2010.
    [ PubMed Abstract ]
  • Saleiro D, Murillo G, Lubahn DB, Kopelovich L, Korach KS, Mehta RG. Enhanced induction of mucin-depleted foci in estrogen receptor Β knockout mice. Cancer Prev Res (Phila) 3:1198-1204, 2010.
    [ PubMed Abstract ]
  • Sharma S, Gao P, Steele VE. Quantitative morphometry of respiratory tract epithelial cells as a tool for testing chemopreventive agent efficacy. Anticancer Res 30:737-42, 2010.
    [ PubMed Abstract ]
  • Steele VE, Lubet RA. The use of animal models for cancer chemoprevention drug development. Semin Oncol 37:327-38, 2010.
    [ PubMed Abstract ]
  • Tang JY, Aszterbaum M, Athar M, Barsanti F, Cappola C, Estevez N, Hebert J, Hwang J, Khaimskiy Y, Kim A, Lu Y, So PL, Tang X, Kohn MA, McCulloch CE, Kopelovich L, Bickers DR, Epstein EH, Jr. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) 3:25-34, 2010.
    [ PubMed Abstract ]
  • Umar A, Della'Zanna G, Lubet R. Further thoughts on preclinical animal models for cancer prevention: When is it best to start treatment? What are potential histopathologic endpoints? Semin Oncol 37:339-44, 2010.
    [ PubMed Abstract ]
  • Wang Y, James M, Wen W, Lu Y, Szabo E, Lubet RA, You M. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther 9:3074-82, 2010.
    [ PubMed Abstract ]
  • Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 70:6566-76, 2010.
    [ PubMed Abstract ]
  • Yang HH, Hu N, Wang C, Ding T, Dunn BK, Goldstein AM, Taylor PR, Lee MP. Influence of genetic background and tissue types on global DNA methylation patterns. PLoS One 5:e9355, 2010.
    [ PubMed Abstract ]
  • Zhang Q, Fu H, Pan J, He J, Ryota S, Hara Y, Wang Y, Lubet RA, You M. Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J Mice. Pharm Res 27:1066-71, 2010.
    [ PubMed Abstract ]

2009

  • Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26;360:1310-1319.
    [ PubMed Abstract ]
  • Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009 Jun 15;486(2): 95-102.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice. Carcinogenesis. 2009 Aug;30(8): 1398-1401.
    [ PubMed Abstract ]
  • Boman B, Kopelovich L, Siracusa LD, Zhang T, Henderson K, Cofer Z, Buchberg AM, Fields JZ, Otevrel T. A Tcf4-GFP reporter mouse model for monitoring effects of Apc mutations during intestinal tumorigenesis. Mol Carcinog. 2009 Sep;48(9):821-31.
    [ PubMed Abstract ]
  • Burgess JP, Green JS, Hill JM, Zhan Q, Lindeblad M, Lyubimov A, Kapetanovic IM, Schwartz A, Thomas BF. Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone. Drug Metab Dispos. 2009 May;37(5):1089-97.
    [ PubMed Abstract ]
  • D'Agostini F, Mastracci L, Izzotti A, Balansky R, Pennisi TM, Steele VE, De Flora S. Modulation by phenethyl isothiocyanate and budesonide of molecular and histopathologic alterations induced by environmental cigarette smoke in mice. Cancer Prev Res. 2009 Jun;2(6): 546-56.
    [ PubMed Abstract ]
  • Duncan CG, Leary RJ, Lin JC, Cummins J, Di C, Schaefer CF, Wang TL, Riggins GJ, Edwards J, Bigner D, Kopelovich L, Vogelstein B, Kinzler KW, Velculescu VE, Yan H. Identification of microbial DNA in human cancer. BMC Med Genomics. 2009 May 8;2: 22.
    [ PubMed Abstract ]
  • Dunn BK, Ryan A, Ford LG. Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention [Review]. Recent Results Cancer Res. 2009 181:183-93.
    [ PubMed Abstract ]
  • Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: The AMP-activated protein kinase. Cancer Prev Res. 2009 Apr;2(4): 301-9.
    [ PubMed Abstract ]
  • Fu H, He J, Mei F, Zhang Q, Hara Y, Ryota S, Lubet RA, Chen R, Chen DR, You M. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev Res. 2009 Jun;2(6): 531-7.
    [ PubMed Abstract ]
  • Gorman GS, Coward L, Kerstner-Wood C, Freeman L, Hebert CD, Kapetanovic IM. In-vitro and in-vivo metabolic studies of the candidate chemopreventative pentamethylchromanol using liquid chromatography/tandem mass spectrometry. J Pharm Pharmacol. 2009 Oct;61(10): 1309-18.
    [ PubMed Abstract ]
  • Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res. 2009 2: 114-121. Erratum in: Cancer Prev Res ( Phila Pa ). 2009 Mar;2(3):283. Comment in: Cancer Prev Res ( Phila Pa ). 2009 Feb;2(2):97-9.
    [ PubMed Abstract ]
  • Greenwald P, Dunn BK. Landmarks in the history of cancer epidemiology. Cancer Res. 2009; Mar 15;69(6):2151-62. Erratum in: Cancer Res. 2009 Aug 15;69(16):6758.
    [ PubMed Abstract ]
  • Greenwald P, Dunn BK. Do we make optimal use of the potential of cancer prevention? [Review]. Recent Results Cancer Res. 2009 181:3-17.
    [ PubMed Abstract ]
  • Itano O, Yang K, Fan K, Kurihara N, Shinozaki H, Abe S, Jin B, Gravaghi C, Edelmann W, Augenlicht L, Kopelovich L, Kucherlapati R, Lamprecht S, Lipkin M. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis. 2009 Nov;30(11):1923-26.
    [ PubMed Abstract ]
  • Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 2009 23: 806-12.
  • Izzotti A, Calin GA, Steele VE, Croce CM, De Flora S. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J. 2009 23: 3243-50.
  • Izzotti A, D'Agostini F, Larghero P, Cartiglia C, Travaini G, Balansky R, Steele VE, De Flora S. Upregulation of stem cell antigen-1 in the lung of neonatal mice exposed to environmental cigarette smoke. Oncol Rep. 2009 Sep;22(3): 469-74.
    [ PubMed Abstract ]
  • Jackson JP, Kabirov KK, Kapetanovic IM, Lyubimov A. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3): 263-72.
    [ PubMed Abstract ]
  • Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: Chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res. 2009 Jan;2(1): 52-59.
    [ PubMed Abstract ]
  • Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T, Tsukada K, Dunn BK, Wakefield LM, Lee MP. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009 Sep 15;69(18):7357-65.
    [ PubMed Abstract ]
  • Kapetanovic IM. Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3): 698-700.
    [ PubMed Abstract ]
  • Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R, Lyubimov A. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Chem Biol Interact. 2009 May 15;179(2-3): 233-9.
    [ PubMed Abstract ]
  • Kapetanovic IM, Crowell JA, Krishnaraj R, Zakharov A, Lindeblad M, Lyubimov A. Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs. Toxicology. 2009 Jun 16;260(1-3): 28-36.
    [ PubMed Abstract ]
  • Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: Role of imaging. AJR Am J Roentgenol. 2009 Jun;192(6): 1455-70.
    [ PubMed Abstract ]
  • Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res. 2009 Feb;2(2): 161-7.
    [ PubMed Abstract ]
  • Lubet RA, Yao R, Grubbs CJ, You M, Wang Y. Induced expression of drug metabolizing enzymes by preventive agents: Role of the antioxidant response element. Chem Biol Interact. 2009 Nov 10;182(1): 22-8.
    [ PubMed Abstract ]
  • Lee N, Laine AF, Marquez G, Levsky JM, Gohagan JK. Potential of computer-aided diagnosis to improve CT lung cancer screening. IEEE Reviews in Biomedical Engineering. 2009 Dec 2:136-146.
  • Miller JH, Kramer BS, Kreimer AR, Prorok PC, Xu J-L, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE. Cumulative incidence of false-positive results in repeated, multi-modality cancer screening. Ann Fam Med. 2009 May/June 7(3):212-222.
    [ PubMed Abstract ]
  • Rao CV, Steele VE, Stoner GD, Conney AH. Bandaru S. Reddy: In memoriam (1930-2009). Cancer Prev Res. 2009 2: 912-13.
  • Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res. 2009 Oct 15;69(20): 8175-82.
    [ PubMed Abstract ]
  • Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA. Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res. 2009 Nov;2(11): 951-6.
    [ PubMed Abstract ]
  • Vydelingum NA (member of the HHS Interagency Workgroup for the NHQR/NHDR). 2008 National Healthcare Disparities Report. Rockville, MD: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality; March 2009. AHRQ Pub. No. 09-0002.
  • Wang Y, Wen W, Yi Y, Zhang Z, Lubet RA, You M. Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev Res. 2009 Dec;2(12): 1059-64.
    [ PubMed Abstract ]
  • Wang Y, Zhang Z, Garbow JR, Rowland DJ, Lubet RA, Sit D, Law F, You M. Chemoprevention of lung squamous cell carcinoma in mice by a mixture of Chinese herbs. Cancer Prev Res. 2009 Jul;2(7): 634-40.
    [ PubMed Abstract ]
  • Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res. 2009 Jan 15;69(2): 687-94.
    [ PubMed Abstract ]

2008

  • Alyaqoub FS, Liu Y, Tao L, Steele VE, Lubet RA, Pereira MA . Modulation by bexarotene of mRNA expression of genes in mouse lung tumors. Mol Carcinog. 2008 Mar;47(3): 165-71.
    [ PubMed Abstract ]
  • Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, Devarajan K, Lubet RA, Cooper HS. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2008 Oct;14(10): 1341-47.
    [ PubMed Abstract ]
  • D'Agostini F, Balansky R, Steele VE, Ganchev G, Pesce C, De Flora S. Preneoplastic and neoplastic lesions in the lung, liver and urinary tract of mice exposed to environmental cigarette smoke and UV light since birth. Int J Cancer. 2008 Dec 1;123(11): 2497-2502.
    [ PubMed Abstract ]
  • De Flora S, D'Agostini F, Balansky R, Camoirano A, Cartiglia C, Longobardi M, Travaini G, Steele VE, Pesce C, Izzotti A. High susceptibility of neonatal mice to molecular, biochemical and cytogenetic alterations induced by environmental cigarette smoke and light. Mutat Res. 2008 Jul-Aug;659(1-2): 137-46.
    [ PubMed Abstract ]
  • Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT, Gautier J. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008 Feb;4(2): 119-25.
    [ PubMed Abstract ]
  • Furimsky AM, Green CE, Sharp LE, Catz P, Adjei AA, Parman T, Kapetanovic IM, Weinshilboum RM, Iyer LV. Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metab Dispos. 2008 Jan;36(1): 129-36.
    [ PubMed Abstract ]
  • Garbow JR, Wang M, Wang Y, Lubet RA, You M. Quantitative monitoring of adenocarcinoma development in rodents by magnetic resonance imaging. Clin Cancer Res. 2008 Mar 1;14(5): 1363-67.
    [ PubMed Abstract ]
  • Guruswamy S, Swamy MV, Choi CI, Steele VE, Rao CV. S-adenosyl L-methionine inhibits azoxymethane-induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco-2 cell growth in 3D culture. Int J Cancer. 2008 Jan 1;122(1): 25-30.
    [ PubMed Abstract ]
  • Izzotti A, D'Agostini F, Balansky R, Degan P, Pennisi TM, Steele VE, De Flora S. Exposure of mice to cigarette smoke and/or light causes DNA alterations in heart and aorta. Mutat Res. 2008 Sep 26;644(1-2): 38-42.
    [ PubMed Abstract ]
  • Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV. Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells. Mol Cancer Ther. 2008 Jan;7(1): 181-90.
    [ PubMed Abstract ]
  • Janakiram NB, Indranie C, Malisetty SV, Jagan P, Steele VE, Rao CV. Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res. 2008 Sep;25(9): 2151-7.
    [ PubMed Abstract ]
  • Johnson WD, Morrissey RL, Kapetanovic I, Crowell JA, McCormick DL. Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention. Food Chem Toxicol. 2008 Mar;46(3): 1068-78.
    [ PubMed Abstract ]
  • Kabirov KK, Kapetanovic IM, Lyubimov AV. Direct determination of selenium in rat blood plasma by Zeeman atomic absorption spectrometry. Chem Biol Interact. 2008 Jan 30;171(2): 152-8.
    [ PubMed Abstract ]
  • Kapetanovic IM. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chem Biol Interact. 2008 Jan 30;171(2): 165-76.
    [ PubMed Abstract ]
  • Kapetanovic IM, Lyubimov A: Analytical Chemistry Methods- Developments and Validation. in Gad SC (ed) Preclinical Development Handbook: ADME and Biopharmaceutical Properties, Wiley-Interscience, ISBN 978-0-470-24847-8 (2008), Hoboken, NJ, Ch. 5, pp. 151-210.
    [ Handbook Information Link Exit Disclaimer ]
  • Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjoblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA . 2008 Oct 21;105(42): 16224-9.
    [ PubMed Abstract ]
  • Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 2008 Nov 15;123(10): 2254-9.
    [ PubMed Abstract ]
  • Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. Mol Cancer Ther. 2008 Apr;7(4): 972-9.
    [ PubMed Abstract ]
  • Martin-Jimenez T, Lindeblad M, Kapetanovic IM, Chen Y, Lyubimov A. Comparing pharmacokinetic and pharmacodynamic profiles in female rats orally exposed to lovastatin by gavage versus diet. Chem Biol Interact. 2008 Jan 30;171(2): 142-51.
    [ PubMed Abstract ]
  • Mehta RG, Naithani R, Huma L, Hawthorne M, Moriarty RM, McCormick DL, Steele VE, Kopelovich L. Efficacy of chemopreventive agents in mouse mammary gland organ culture (MMOC) model: a comprehensive review. Curr Med Chem. 2008;15(27): 2785-825.
    [ PubMed Abstract ]
  • Micale RT, D'Agostini F, Steele VE, La Maestra S, De Flora S. Budesonide and phenethyl isothiocyanate attenuate DNA damage in bronchoalveolar lavage cells of mice exposed to environmental cigarette smoke. Curr Cancer Drug Targets. 2008 Dec;8(8): 703-8.
    [ PubMed Abstract ]
  • Pearce VP, Sherrell J, Lou Z, Kopelovich L, Wright WE, Shay JW. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene. 2008 Apr 10;27(17): 2365-74.
    [ PubMed Abstract ]
  • Rao CV, Joseph S, Gao L, Patlolla JM, Choi CI, Kopelovich L, Steele VE, Rigas B. Pharmaco-kinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. Int J Oncol. 2008 33: 799-805.
    [ PubMed Abstract ]
  • Rao CV, Swamy MV, Patlolla JM, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res. 2008 Sep 15;68(18): 7670-5.
    [ PubMed Abstract ]
  • Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10): 2619-24.
    [ PubMed Abstract ]
  • Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3): 674-9.
    [ PubMed Abstract ]
  • Rosenfeld S, Kapetanovic IM. Systems biology and cancer prevention: All options on the table. Gene Regul Syst Bio. 2008 Oct 10;2: 307-19.
    [ PubMed Abstract ]
  • Stewart J, Ware J, Boysen C, Gulati S, Zhou Z, Rosenfeld S, Kopelovich L, Kennedy AR. Effects of selenomethionine on the gene expression profile of cloned human prostate cancer cells representing a phenotypic continuum of cancer progression. Nutr Cancer. 2008; 60(6): 826-36.
    [ PubMed Abstract ]
  • Tang X, Kim AL, Kopelovich L, Bickers DR, Athar M. Cyclooxygenase-2 inhibitor Nimesulide blocks ultraviolet -induced photocarcinogenesis in SKH-1 Hairless Mice. Photochem Photobiol. 2008 Mar-Apr;84(2): 522-7.
    [ PubMed Abstract ]
  • Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE . Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6): 1411-7.
    [ PubMed Abstract ]
  • Wang Y, Zhang Z, Lu Y, Yao R, Jia D, Wen W, LaRegina M, Crist K, Lubet R, You M. Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation. Mol Cancer Res. 2008 6: 99-109.
    [ PubMed Abstract ]
  • Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN. Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res. 2008;10(1): R18.
    [ PubMed Abstract ]
  • Yang K, Lamprecht SA, Shinozaki H, Fan K, Yang W, Newmark HL, Kopelovich L, Edelmann W, Jin B, Gravaghi C, Augenlicht L, Kucherlapati R, Lipkin M. Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice. J Nutr. 2008 Sep;138(9): 1658-63.
    [ PubMed Abstract ]
  • Yeung AT, Patel BB, Li XM, Seeholzer SH, Coudry RA, Cooper HS, Bellacosa A, Boman BM, Zhang T, Litwin S, Ross EA, Conrad P, Crowell JA, Kopelovich L, Knudson A. One-hit effects in cancer: Altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res. 2008 Sep 15;68(18): 7579-86.
    [ PubMed Abstract ]

2007

  • Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 2007 Nov 1;224(3):274-83.
    [ PubMed Abstract ]
  • Balansky R, Ganchev G, Iltcheva M, Steele VE, D'Agostini F, De Flora S. Potent carcinogenicity of cigarette smoke in mice exposed early in life. Carcinogenesis. 2007 Oct;28(10):2236-43. Epub 2007 May 23.
    [ PubMed Abstract ]
  • Chalut KJ, Kresty LA, Pyhtila JW, Nines R, Baird M, Steele VE, Wax A. In situ assessment of intraepithelial neoplasia in hamster trachea epithelium using angle-resolved low-coherence interferometry. Cancer Epidemiol Biomarkers Prev 16 (2): 223-7, 2007.
    [ PubMed Abstract ]
  • Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 2007 Aug;6(8):2139-48. Review.
    [ PubMed Abstract ]
  • Doppalapudi RS, Riccio ES, Rausch LL, Shimon JA, Lee PS, Mortelmans KE, Kapetanovic IM, Crowell JA, Mirsalis JC. Evaluation of chemopreventive agents for genotoxic activity. Mutat Res. 2007 May 18;629(2):148-60.
    [ PubMed Abstract ]
  • Elmore E, Jain A, Siddiqui S, Tohidian N, Meyskens FL, Steele VE, Redpath JL. Development and characteristics of a human cell assay for screening agents for melanoma prevention. Melanoma Res 17 (1): 42-50, 2007.
    [ PubMed Abstract ]
  • Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
    [ PubMed Abstract ]
  • Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, McCormick DL. Oncogenicity evaluation of resveratrol in p53((+/-)) (p53 knockout) mice. Food Chem Toxicol. 45:55-63, 2007
    [ PubMed Abstract ]
  • Horn TL, Torres KE, Naylor JM, Cwik MJ, Detrisac CJ, Kapetanovic IM, Lubet RA, Crowell JA, McCormick DL. Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats. Toxicol Sci. 2007 Oct;99(2):612-27. Epub 2007 Jul 14.
    [ PubMed Abstract ]
  • Li L, Tao L, Lubet RA, Steele VE, Pereira MA. Modulation by budesonide of a CpG endonuclease in mouse lung tumors. Carcinogenesis. 2007 Jul;28(7):1499-503. Epub 2007 Mar 14.
    [ PubMed Abstract ]
  • Lubet RA, Yang CS, Lee MJ, Hara Y, Kapetanovic IM, Crowell JA, Steele VE, Juliana MM, Grubbs CJ. Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols. Mol Cancer Ther. 2007 Jul;6(7):2022-8.
    [ PubMed Abstract ]
  • McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr Cancer. 2007;57(2):184-93.
    [ PubMed Abstract ]
  • McCormick DL, Johnson WD, Haryu TM, Bosland MC, Lubet RA, Steele VE. Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat. Nutr Cancer. 2007;57(2):194-200.
    [ PubMed Abstract ]
  • McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, Bosland MC. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis. 2007 Feb;28(2):398-403. Epub 2006 Sep 3.
    [ PubMed Abstract ]
  • Pereira MA, Tao L, Liu Y, Li L, Steele VE, Lubet RA. Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int J Cancer 120 (5): 1150-3, 2007.
    [ PubMed Abstract ]
  • Ware JH, Zhou Z, Guan J, Kennedy AR, Kopelovich L. Establishment of human cancer cell clones with different characteristics: a model for screening chemopreventive agents. Anticancer Res 27 (1A): 1-16, 2007.
    [ PubMed Abstract ]

2006

  • Ali IU,
  • Ali IU, Xiao Z, Malone W, Smith M, Conrads TP, Veenstra TD, Greenwald P, Luke BT, McLarty JW. Plasma proteomic profiling: search for lung cancer diagnostic and early detection markers. Oncol Rep 15 (5): 1367-1372, 2006.
    [ PubMed Abstract ]
  • Alyaqoub FS, Tao L, Kramer PM, Steele VE, Lubet RA, Gunning WT, Pereira MA. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT). Carcinogenesis, 2006, (in press).
    [ PubMed Abstract ]
  • Arif JM, Dresler C, Clapper ML, Gairola CG, Srinivasan C, Lubet RA, Gupta RC. Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. Chem Res Toxicol 19 (2): 295-299, 2006.
    [ PubMed Abstract ]
  • Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermatol 15 (9): 667-677, 2006.
    [ PubMed Abstract ]
  • Balansky R, D'Agostini F, Ganchev G, Izzotti A, Di Marco B, Lubet RA, Zanesi N, Croce CM, De Flora S. Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: chemoprevention by budesonide and N-acetylcysteine. Proc Natl Acad Sci USA 103 (20): 7823-7828, 2006.
    [ PubMed Abstract ]
  • Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, Brenner DE, Booth TD, Gescher A, Steward WP. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, (in press).
    [ PubMed Abstract ]
  • Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, Green AG, Bradford WW, Green CE, Kapetanovic IM, Iyer LV. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol 58 (4): 469-479, 2006.
    [ PubMed Abstract ]
  • Burgess JP, Wintermute JS, Thomas BF, Kapetanovic IM. Complete (1)H and (13)C assignments of fluorinated analogs of dehydroepiandrosterone. Magn Reson Chem 44 (11): 1051-3, 2006.
    [ PubMed Abstract ]
  • Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, Balakireva MG, Romeo Y, Kopelovich L, Gale M, Jr., Yeaman C, Camonis JH, Zhao Y, White MA. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127 (1): 157-70, 2006.
    [ PubMed Abstract ]
  • Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15 (12): 2473-6, 2006.
    [ PubMed Abstract ]
  • Crowell JA, Page JG, Levine BS, Tomlinson MJ, Hebert CD. Indole-3-carbinol, but not its major digestive product 3,3'-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450. Toxicol Appl Pharmacol. 211 (2): 115-123, 2006.
    [ PubMed Abstract ]
  • Gerhauser C, Bartsch H, Crowell J, Flora SD, D'Incalci M, Dittrich C, Frank N, Mihich E, Steffen C, Tortora G, Gescher A. Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising Phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. Eur J Cancer 42 (10): 1338-1343, 2006.
    [ PubMed Abstract ]
  • Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 27 (6): 1232-1239, 2006.
    [ PubMed Abstract ]
  • Huang Y, Yan J, Lubet R, Kensler TW, Sutter TR. Identification of novel transcriptional networks in response to treatment with the anticarcinogen 3H-1,2-dithiole-3-thione. Physiol Genomics 24 (2): 144-153, 2006.
    [ PubMed Abstract ]
  • Johnson WD, Dooley L, Morrissey RL, Arp L, Kapetanovic I, Crowell JA, McCormick DL. Oncogenicity evaluations of chemopreventive soy components in p53((+/-)) (p53 knockout) mice. Int J Toxicol. 25 (3): 219-228, 2006.
    [ PubMed Abstract ]
  • Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers DR, Athar M. Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 15 (7): 538-546, 2006.
    [ PubMed Abstract ]
  • Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10, 2006.
    [ PubMed Abstract ]
  • Lu Y, Yao R, Yan Y, Wang Y, Hara Y, Lubet RA, You M. A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. Cancer Res 66 (4): 1956-1963, 2006.
    [ PubMed Abstract ]
  • Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ. Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Mol.Cancer Ther  5 (4): 1073-1078, 2006.
    [ PubMed Abstract ]
  • McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, Bosland MC. Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis, 2006, (in press).
    [ PubMed Abstract ]
  • Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ, Jr., Broxmeyer HE, Kopelovich L, Nakshatri H. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene, 2006, (in press).
    [ PubMed Abstract ]
  • Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 66 (8): 4503-4511, 2006.
    [ PubMed Abstract ]
  • Pereira MA, Kramer PM, Nines R, Liu Y, Alyaqoub FS, Gunning WT, Steele VE, Lubet RA. Prevention of mouse lung tumors by targretin. Int J Cancer 118 (9): 2359-2362, 2006.
    [ PubMed Abstract ]
  • Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 5 (6): 1530-1538, 2006.
    [ PubMed Abstract ]
  • Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, Rao CV. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66 (8): 4542-4546, 2006.
    [ PubMed Abstract ]
  • Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA, Hurwitz A. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev 15 (12): 2477-81, 2006.
    [ PubMed Abstract ]
  • Sharma S, Gao P, Steele VE. The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model. Carcinogenesis 27 (8): 1721-1727, 2006.
    [ PubMed Abstract ]
  • Steele VE, Arnold JT, Lei H, Izmirlian G, Blackman MR. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res 26 (5A): 3205-15, 2006.
    [ PubMed Abstract ]
  • Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 66 (14): 7370-7377, 2006.
    [ PubMed Abstract ]
  • Verschoyle RD, Greaves P, Cai H, Borkhardt A, Broggini M, D'Incalci M, Riccio E, Doppalapudi R, Kapetanovic IM, Steward WP, Gescher AJ. Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemother.Pharmacol. 57 (1): 1-6, 2006.
    [ PubMed Abstract ]
  • Wang Y, Yao R, Maciag A, Grubbs CJ, Lubet RA, You M. Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Mol Cancer Ther  5 (4): 1060-1072, 2006.
    [ PubMed Abstract ]
  • Wang Y, Zhang Z, Lubet RA, You M. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene 25 (8): 1277-1280, 2006.
    [ PubMed Abstract ]
  • Wang Y, Zhang Z, Yao R, Jia D, Wang D, Lubet RA, You M. Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 25 (9): 1320-1329, 2006.
    [ PubMed Abstract ]
  • Ware JH, Zhou Z, Kopelovich L, Kennedy AR. Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line. Anticancer Res 26 (6B): 4177-83, 2006.
    [ PubMed Abstract ]
  • Woditschka S, Haag JD, Waller JL, Monson DM, Hitt AA, Brose HL, Hu R, Zheng Y, Watson PA, Kim K, Lindstrom MJ, Mau B, Steele VE, Lubet RA, Gould MN. Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. Cancer Res  66 (13): 6884-6891, 2006.
    [ PubMed Abstract ]
  • Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, Lubet RA, You M. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 4 (12): 971-81, 2006.
    [ PubMed Abstract ]
  • Yan Y, Wang Y, Tan Q, Hara Y, Yun TK, Lubet RA, You M. Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia 8 (1): 52-58, 2006.
    [ PubMed Abstract ]
  • Yao R, Wang Y, Lu Y, Lemon WJ, End DW, Grubbs CJ, Lubet RA, You M. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: Role of Ha-ras mutations and use of microarray analysis to identify potential targets. Carcinogenesis 27 (7): 1420-31, 2006.
    [ PubMed Abstract ]
  • Zhang Z, Wang Y, Yao R, Li J, Lubet RA, You M. p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer. Mol Cancer Res  4 (6): 401-410, 2006.
    [ PubMed Abstract ]

2005

    Catz P, Shinn W, Kapetanovic IM, Kim H, Kim M, Jacobson EL, Jacobson MK, Green CE: Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chrom. B Analyt Technol Biomed Life Sci. 829:123-35, 2005.
    [ PubMed Abstract ]
  • Crist, K.A., Zhang, Z., You, M., Gunning, W.T., Conran, P.B., Steele, V.E., and Lubet R.A. Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethyldenz[a]anthracene (DMBA) coated suture. Carcinogenesis 26:951-957, 2005.
    [ PubMed Abstract ]
  • Elmore, E., Siddiqui, S., Navidi, M., Steele, V.E., and Redpath, L. Correlation of In Vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. J Cell Biochem, 95:571-588, 2005.
    [ PubMed Abstract ]
  • Horn TL, Long L, Cwik MJ, Morrissey RL, Kapetanovic IM, McCormick DL: Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. Chemico-Biol. Interact. 152:79-99, 2005.
    [ PubMed Abstract ]
  • Lubet, R.A., Christov, K., Nunez, N.P., Hursting, S.D., Steele, V.E., Juliana, M.M., Eto, I., Grubbs, C.J. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis. 26(2):441-448, 2005.
    [ PubMed Abstract ]
  • Lubet, R.A., Huebner, K., Fong, L.Y.Y., Altieri, D.C., Steele, V.E., Kopelovich, L., Kavanaugh, C., Juliana, M.M., Soong, S., and Grubbs, C.J. N-Butyl-N(4 hydroxybutyl)-nitrosamine (OH-BBN) - induced urinary bladder cancers in mice: Characterization of FHIT, survivin expression, and chemoprevention effects of indomethacin. Carcinogenesis 26(3): 571-578, 2005.
    [ PubMed Abstract ]
  • Raju, J., Swamy, M.V., Cooma, I., Patlolla, J.M.R., Pittman, B., Reddy, B.S., Steele, V.E., and Rao, C.V. Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. Int J Cancer. 113(5):798-802, 2005.
    [ PubMed Abstract ]
  • Simeone, A-M, Deng, C-X, Kelloff, G.J., Steele, V.E., Johnson, M.M., and Tari, A.M. Inhibitory effects of N-(4-hydroxyphenyl)retinamide and other phenylretinamides against BRCA-1 mutated breast cancer cells. Carcinogenesis, 26:1000-1007, 2005.
    [ PubMed Abstract ]
  • Wax, A., Pyhtila, J.W., Graf, R.N. Graf, Nines, R., Boone, C.W., Dasari, R.R., Feld, M.S., Steele, V.E., and Stoner, G.D. Prospective grading of neoplastic change in rat esophagus using angle-resolve low coherance interferometry. Journal of Miomedical Optics 10(5): 051604-01-10, 2005.
    [ PubMed Abstract ]

2004

  • Almahmeed T, Boyle JO, Cohen EG, Carew JF, Du B, Altorki NK, Kopelovich L, Fang JL, Lazarus P, Subbaramaiah K, Dannenberg AJ. (2004) Benzo[a]pyrene phenols are more potent inducers of CYPlAl, CYP1B1 and COX-2 than benzo[a]pyrene glucuronides in cell lines derived from the human aerodigestive tract. Carcinogenesis. Jan 16
    [ PubMed Abstract ]
  • Bonner AE, Lemon WJ, Devereux TR, Lubet RA, You M. (2004) Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene. Feb 5;23(5):1166-76.
    [ PubMed Abstract ]
  • Cope MB, Steele VE, Lubet RA, Eto I, Juliana MM, Hill DL, Grubbs CJ. (2004) Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. Oncol Rep. Feb;11(2):465-9.
    [ PubMed Abstract ]
  • Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Steele VE, Wattenberg LW. (2004) Effect of chemopreventive agents on separate stages of progression of benzo[a]pyrene induced lung tumors in A/J mice. Carcinogenesis. Feb;25(2):197-201.
    [ PubMed Abstract ]
  • Kapetanovic IM, Rosenfeld S, Izmirlian G: Overview of commonly used bioinformatics methods and their applications. In: Umar A, Kapetanovic IM, Khan J (eds) The Applications of Bioinformatics in Cancer Detection, Annals of the New York Academy of Sciences, New York, New York, 1020: 10-21, 2004.
  • Kapetanovic IM, Umar A, Khan J: Proceedings of the applications of bioinformatics in cancer detection (ABCD) workshop Exit Disclaimer . In: Umar A, Kapetanovic IM, Khan J (eds) The Applications of Bioinformatics in Cancer Detection, Annals of the New York Academy of Sciences, New York, New York, 1020: 1-9, 2004.
  • Posner GH, Jeona HB, Sarjeanta A, Riccio ES, Doppalapudi RS, Kapetanovic IM, Sahad U, Dolane P, Kensler TW: Low-calcemic, efficacious, 1_,25-dihydroxyvitamin D3 analog QW-1624F2-2: calcemic dose-response determination, preclinical genotoxicity testing, and revision of A-ring stereochemistry. Steroids 69: 757-762, 2004.
  • Tao L, Wang W, Kramer PM, Lubet RA, Steele VE, Pereira MA. (2004) Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol Carcinog. Feb;39(2):79-84.
    [ PubMed Abstract ]
  • Umar A, Kapetanovic IM, Khan J (eds) The Applications of Bioinformatics in Cancer Detection Exit Disclaimer, Annals of the New York Academy of Sciences, New York, New York, v. 1020, pp. 1-277, 2004.
  • Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun. Jan 16;313(3):784-8.
    [ PubMed Abstract ]

2003

  • Balansky RM, Izzotti A, D'Agostini F, Camoirano A, Bagnasco M, Lubet RA, De Flora S. (2003) Systemic genotoxic effects produced by light, and synergism with cigarette smoke in the respiratory tract of hairless mice. Carcinogenesis. Sep;24(9):1525-32.
    [ PubMed Abstract ]
  • Chang PY, Mirsalis J, Riccio ES, Bakke JP, Lee PS, Shimon J, Phillips S, Fairchild D, Hara Y, Crowell JA. (2003) Genotoxicity and toxicity of the potential cancer-preventive agent polyphenon E. Environ Mol Mutagen. 41(1):43-54.
    [ PubMed Abstract ]
  • Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS. (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. Aug 15;9(9):3312-9.
    [ PubMed Abstract ]
  • Christov K, Ikui A, Shilkaitis A, Green A, Yao R, You M, Grubbs C, Steele V, Lubet R, Weinstein IB. (2003) Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat. 77(3):253-64.
    [ PubMed Abstract ]
  • Christov KT, Shilkaitis AL, Kim ES, Steele VE, Lubet RA. (2003 ) Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. Eur J Cancer. 39(2):230-9.
    [ PubMed Abstract ]
  • Crowell JA, Steele VE, Sigman CC, Fay JR. (2003) Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther. Aug;2(8):815-23.
    [ PubMed Abstract ]
  • Crowell JA, Steele VE. (2003) AKT and the phosphatidylinositol 3-kinase/AKT pathway: important molecular targets for lung cancer prevention and treatment. J Natl Cancer Inst. 95(4):252-3.
    [No abstract available.]
  • Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. (2003) Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res. Oct 15;9(13):4722-9.
    [ PubMed Abstract ]
  • De Flora S, Balansky RM, D'Agostini F, Izzotti A, Camoirano A, Bennicelli C, Zhang Z, Wang Y, Lubet RA, You M. (2003) Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke. Cancer Res. 63(4):793-800.
    [ PubMed Abstract ]
  • De Flora S, D'Agostini F, Balansky R, Camoirano A, Bennicelli C, Bagnasco M, Cartiglia C, Tampa E, Longobardi MG, Lubet RA, Izzotti A. (2003) Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis. Mutat Res. 523-524:237-52.
    [ PubMed Abstract ]
  • Ding H, Han C, Gibson-D'Ambrosio R, Steele VE, D'Ambrosio SM. (2003) Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer. Dec 10;107(5):830-6.
    [ PubMed Abstract ]
  • Diwadkar-Navsariwala V, Novotny JA, Gustin DM, Sosman JA, Rodvold KA, Crowell JA, Stacewicz-Sapuntzakis M, Bowen PE. (2003) A physiological pharmacokinetic model describing the disposition of lycopene in healthy men. J Lipid Res. Oct;44(10):1927-39.
    [ PubMed Abstract ]
  • Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA. (2003) Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis. May;24(5):945-52.
    [ PubMed Abstract ]
  • Gunning WT, Kramer PM, Lubet RA, Steele VE, End DW, Wouters W, Pereira MA. (2003) Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. Clin Cancer Res. May;9(5):1927-30.
    [ PubMed Abstract ]
  • Herbert BS, Pearce VP, Hynan LS, LaRue DM, Wright WE, Kopelovich L, Shay JW. (2003) A peroxisome proliferator-activated receptor-gamma agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells. Cancer Res. Apr 15;63(8):1914-9.
    [ PubMed Abstract ]
  • Hu Z, Bonifas JM, Aragon G, Kopelovich L, Liang Y, Ohta S, Israel MA, Bickers DR, Aszterbaum M, Epstein EH Jr. (2003) Evidence for lack of enhanced hedgehog target gene expression in common extracutaneous tumors. Cancer Res. 63(5):923-8.
    [ PubMed Abstract ]
  • Kopelovich L, Crowell JA, Fay JR. (2003) The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst. Dec 3;95(23):1747-57. Review.
    [ PubMed Abstract ]
  • Korytko PJ, Rodvold KA, Crowell JA, Stacewicz-Sapuntzakis M, Diwadkar-Navsariwala V, Bowen PE, Schalch W, Levine BS. (2003) Pharmacokinetics and tissue distribution of orally administered lycopene in male dogs. J Nutr. Sep;133(9):2788-92.
    [ PubMed Abstract ]
  • Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. (2003) Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol. Nov 1;192(3):294-306. Review.
    [ PubMed Abstract ]
  • Li M, Ren S, Tilli MT, Flaws JA, Lubet R, Grubbs CJ, Furth PA. (2003) Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity. Oncogene. May 1;22(17):2568-72.
    [ PubMed Abstract ]
  • Malone W, Perloff M, Crowell J, Sigman C, Higley H. (2003) Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs. Nov;12(11):1829-42.
    [ PubMed Abstract ]
  • Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Jeffcoat RA, Crowell J, Paglieri J, Zeisel SH. (2003) Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr. 77(4):875-82.
    [ PubMed Abstract ]
  • Sabichi AL, Xu H, Fischer S, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Clifford JL. (2003) Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res. Oct 1;9(12):4606-13.
    [ PubMed Abstract ]
  • Steele VE.(2003) Current mechanistic approaches to the chemoprevention of cancer. J Biochem Mol Biol. 36(1):78-81.
    [ PubMed Abstract ]
  • Steele VE, Hawk ET, Viner JL, Lubet RA. (2003) Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 523-524:137-44.
    [ PubMed Abstract ]
  • Swezey RR, Aldridge DE, LeValley SE, Crowell JA, Hara Y, Green CE. (2003) Absorption, tissue distribution and elimination of 4-[(3)h]-epigallocatechin gallate in beagle dogs. Int J Toxicol. May-Jun;22(3):187-93.
    [ PubMed Abstract ]
  • Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC. (2003) Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev. Nov;12(11 Pt 1):1213-21.
    [ PubMed Abstract ]
  • Wan XS, Zhou Z, Kennedy AR, Kopelovich L. (2003) In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells. Oncol Rep. Nov-Dec;10(6):2009-14.
    [ PubMed Abstract ]
  • Wan XS, Zhou Z, Steele V, Kopelovich L, Kennedy AR. (2003) Establishment and characterization of sublines of LNCaP human prostate cancer cells. Oncol Rep. Sep-Oct;10(5):1569-75.
    [ PubMed Abstract ]
  • Wang Y, Zhang Z, Kastens E, Lubet RA, You M. (2003) Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res. Aug 1;63(15):4389-95.
    [ PubMed Abstract ]
  • Wax A, Yang C, Muller MG, Nines R, Boone CW, Steele VE, Stoner GD, Dasari RR, Feld MS. (2003) In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry. Cancer Res. Jul 1;63(13):3556-9.
    [ PubMed Abstract ]
  • Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas B. . (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. Nov 15;63(22):7613-8.
    [ PubMed Abstract ]
  • Yang K, Fan K, Kurihara N, Shinozaki H, Rigas B, Augenlicht L, Kopelovich L, Edelmann W, Kucherlapati R, Lipkin M. (2003) Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 24(3):605-611.
    [ PubMed Abstract ]
  • Yao R, Wang Y, Lubet RA, You M. (2003) Differential gene expression in chemically induced mouse lung adenomas. Neoplasia 5(1):41-52.
    [ PubMed Abstract ]
  • Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. (2003) Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene. Sep 18;22(40):6257-65.
    [ PubMed Abstract ]

2002

  • An KP, Athar M, Tang X, Katiyar SK, Russo J, Beech J, Aszterbaum M, Kopelovich L, Epstein EH Jr, Mukhtar H, Bickers DR. (2002) Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol. 76(1):73-80.
    [ PubMed Abstract ]
  • Benkins SW, Hockett R Jr., Grizzle W, Weiss, HL, Pickens, A, Perloff, M, Malone, WF, Bland KI. (2002) Transforming growth factor-alpha: a surrogate endpoint biomarker? J Am Coll Surg 195(2):149-158.
    [ PubMed Abstract ]
  • Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. (2002) Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 76(5):1126-37.
    [ PubMed Abstract ]
  • Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, Heizer WD, Thomas BF, Hill JM, Crowell JA, Zeisel SH. (2002) Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr. 75:126-136.
    [ PubMed Abstract ]
  • Chen X, Li N, Wang S, Hong J, Fang M, Yousselfson J, Yang P, Newman RA, Lubet RA, Yang CS. (2002) Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 23(12):2095-102.
    [ PubMed Abstract ]
  • Christov KT, Moon RC, Lantvit DD, Boone CW, Steele VE, Lubet RA, Kelloff GJ, Pezzuto JM. (2002) 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats. Cancer Res. 15;62(18):5178-82.
    [ PubMed Abstract ]
  • Cope MB, Steele VE, Eto I, Juliana MM, Hill DL, Grubbs CJ. (2002) Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3. Oncol Rep. 9:533-537.
    [ PubMed Abstract ]
  • Elmore E, Siddiqui S, Desai N, Moyer MP, Steele VE, Redpath JL. (2002) The human epithelial cell cytotoxicity assay for determining tissue specific toxicity: method modifications. Methods Cell Sci.;24(4):145-53.
    [ PubMed Abstract ]
  • Gunning WT, Kramer PM, Steele VE, Pereira MA. (2002) Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 62(15):4199-201.
    [ PubMed Abstract ]
  • Katdare M, Kopelovich L, Telang N. (2002) Efficacy of chemopreventive agents for growth inhibition of Apc [+/-] 1638NCOL colonic epithelial cells. (2002) Int J Mol Med. 10(4):427-32.
    [ PubMed Abstract ]
  • Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JE. (2002) Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res. 11(6):617-33.
    [ PubMed Abstract ]
  • Kopelovich L, Fay JR, Glazer RI, Crowell JA. (2002) Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther. 1:357-363.
  • Lee SK, Heo YH, Steele VE, Pezzuto JM. (2002) Induction of apoptosis by 1,4-phenylenebis(methylene)selenocyanate in cultured human colon cancer cells. Anticancer Res. 22:97-102.
    [ PubMed Abstract ]
  • Madhukar BV, Dimitrov NV, Meyer-Leece C, Contreras ML, Crowell J. (2002) Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz. Mol Cancer Ther. 1(12):1125-8.
    [ PubMed Abstract ]
  • McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. (2002) Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res. 8:1127-1138.
    [ PubMed Abstract ]
  • McDoniels-Silvers AL, Stoner GD, Lubet RA, You M. (2002) Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia. 4:141-150.
    [ PubMed Abstract ]
  • Misra RR, Hursting SD, Perkins SN, Sathyamoorthy N, Mirsalis JC, Riccio ES, Crowell JA. (2002) Genotoxicity and carcinogenicity studies of soy isoflavones. Int J Toxicol. 21(4):277-85.
    [ PubMed Abstract ]
  • Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, Kopelovich L, Nakagawa H, Rustgi AK. (2002) A mouse model of human oral-esophageal cancer. J Clin Invest. 110(6):761-9.
    [ PubMed Abstract ]
  • Pereira MA, Li Y, Gunning WT, Kramer PM, Al-Yaqoub F, Lubet RA, Steele VE, Szabo E, Tao L. (2002) Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis. 2002 Jul;23(7):1185-92.
    [ PubMed Abstract ]
  • Rodriguez-Burford C, Steele VE, Anderson AS, Stockard CR, Weiss HL, Eto I, Johanning GL, Grizzle WE, Grubbs CJ. (2002) Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology. Nutr Cancer. 43(1):67-75.
    [ PubMed Abstract ]
  • Sharma S, Wilkinson BP, Gao P, Steele VE. (2002) Differential Activity of NO Synthase Inhibitors as Chemopreventive Agents in a Primary Rat Tracheal Epithelial Cell Transformation System. Neoplasia. 4:332-336.
    [ PubMed Abstract ]
  • Steele VE, Boone CW, Dauzonne D, Rao CV, Bensasson RV. (2002) Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon. Cancer Res. 62(22):6506-9.
    [ PubMed Abstract ]
  • Sutter TR, He XR, Dimitrov P, Xu L, Narasimhan G, George EO, Sutter CH, Grubbs C, Savory R, Stephan-Gueldner M, Kreder D, Taylor MJ, Lubet R, Patterson TA, Kensler TW. (2002) Multiple comparisons model-based clustering and ternary pattern tree numerical display of gene response to treatment: procedure and application to the preclinical evaluation of chemopreventive agents. Mol Cancer TherDec;1(14):1283-92
    [ PubMed Abstract ]
  • Tao L, Kramer PM, Wang W, Yang S, Lubet RA, Steele VE, Pereira MA. (2002) Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis. 23(9):1447-54.
    [ PubMed Abstract ]
  • Tao L, Li Y, Wang W, Kramer PM, Gunning WT, Lubet RA, Steele VE, Pereira MA. (2002) Effect of budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors. Mol Carcinog. 35(2):93-102.
    [ PubMed Abstract ]
  • Wan XS, Serota DG, Ware JH, Crowell JA, Kennedy AR. (2002) Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate. Nutr. Cancer 43(2):167-73.
    [ PubMed Abstract ]
  • Yao R, Wang Y, Lubet RA, You M. (2002) Differentially expressed genes associated with mouse lung tumor progression. Oncogene. 22;21(37):5814-21.
    [ PubMed Abstract ]
  • Zhang Z, Li J, Lantry LE, Wang Y, Wiseman RW, Lubet RA, You M. (2002) p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas. Cancer Res. 62:3024-3029.
    [ PubMed Abstract ]

2001

  • Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y. (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev. 10:53-58.
    [ PubMed Abstract ]
  • Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Lippman SM. (2001) Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev. 10:391-395.
    [ PubMed Abstract ]
  • Cohen LA, Zhao Z, Pittman B, Aliaga C, Lubet R. (2001) Feeding thiol-containing compounds, derived from vegetables, fails to inhibit N-methylnitrosourea-induced mammary tumorigenesis. Cancer Detect Prev. 25:254-261.
    [ PubMed Abstract ]
  • Crowell JA, Holmes CJ. (2001) Agent identification and preclinical testing. Cancer Treat Res. 106:1-30.
    [ PubMed Abstract ]
  • D'Agostini F, Balansky RM, Bennicelli C, Lubet RA, Kelloff GJ, De Flora S. (2001) Pilot studies evaluating the lung tumor yield in cigarette smoke-exposed mice. Int J Oncol. 18:607-615.
    [ PubMed Abstract ]
  • D'Agostini F, Balansky RM, Izzotti A, Lubet RA, Kelloff GJ, De Flora S. (2001) Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis. 22:375-380.
    [ PubMed Abstract ]
  • D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, Casto B, Milo GE, Kelloff GJ, Steele VE. (2001) Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res. 21:3229-3235.
    [ PubMed Abstract ]
  • Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Gardiner J, Crowell J, Hawk E, Nashawaty M, Bennett JL. (2001) Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev. 10:201-207.
    [ PubMed Abstract ]
  • Elmore E, Luc TT, Steele VE, Redpath JL. (2001) Comparative tissue-specific toxicities of 20 cancer preventive agents using cultured cells from 8 different normal human epithelia. In Vitr Mol Toxicol. 14:191-207.
    [ PubMed Abstract ]
  • Elmore E, Stringer DE, Steele VE, Gerner EW, Redpath JL. (2001) Chemoprevention by difluoromethylornithine: correlation of an in vitro human cell assay with human clinical data for biomarker modulation. Anticancer Res. 21:1163-1165.
    [ PubMed Abstract ]
  • Fischer SM, Lee M, Lubet RA. (2001) Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis. 22:83-88.
    [ PubMed Abstract ]
  • Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R. (2001) 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 61:7449-7455.
    [ PubMed Abstract ]
  • Gupta A, Nines R, Rodrigo KA, Aziz RA, Carlton PS, Gray DL, Steele VE, Morse MA, Stoner GD. (2001) Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat. J Natl Cancer Inst. 93:990-998.
    [ PubMed Abstract ]
  • Hebert JL, Khugyani F, Athar M, Kopelovich L, Epstein EH, Jr., Aszterbaum M. (2001) Chemoprevention of basal cell carcinomas in the ptc1+/- mouse--green and black tea. Skin Pharmacol Appl Skin Physiol. 14:358-362.
    [ PubMed Abstract ]
  • Herbert BS, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW. (2001) Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst. 93:39-45.
    [ PubMed Abstract ]
  • Herzog CR, Crist KA, Sabourin CL, Kelloff GJ, Boone CW, Stoner GD, You M. (2001) Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas. Mol Carcinog. 30:159-168.
    [ PubMed Abstract ]
  • Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. (2001) Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 10:249-259.
    [ PubMed Abstract ]
  • Izzotti A, Balansky RM, Dagostini F, Bennicelli C, Myers SR, Grubbs CJ, Lubet RA, Kelloff GJ, De Flora S. (2001) Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. Cancer Res. 61:2472-2479.
    [ PubMed Abstract ]
  • Johanning GL, Cope MB, Wilborn T, Grubbs CJ, Lubet RA. (2001) Effect of high retinoid doses on RAR-beta mRNA expression in female B6D2F1 mice. Anticancer Res. 21:1691-1695.
    [ PubMed Abstract ]
  • Katdare M, Kopelovich L, Telang N. (2001) Chemopreventive agents inhibit aberrant proliferation of the aneuploid phenotype in a colon epithelial cell line established from Apc 1638N [+/-] mouse. Ann N Y Acad Sci. 952:169-174.
    [ PubMed Abstract ]
  • Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. (2001) Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ. 154:13-26.
    [ PubMed Abstract ]
  • Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC. (2001) Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology. 57:46-51.
    [ PubMed Abstract ]
  • Knott KK, McGinley JN, Lubet RA, Steele VE, Thompson HJ. (2001) Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea. Breast Cancer Res Treat. 70:171-183.
    [ PubMed Abstract ]
  • Liebes L, Conaway CC, Hochster H, Mendoza S, Hecht SS, Crowell J, Chung FL. (2001) High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate. Anal Biochem. 291:279-289.
    [ PubMed Abstract ]
  • Lin L, Wang Y, Bergman G, Kelloff GJ, Lubet RA, You M. (2001) Detection of differentially expressed genes in mouse lung adenocarcinomas. Exp Lung Res. 27:217-229.
    [ PubMed Abstract ]
  • Mehta RG, Bhat KP, Hawthorne ME, Kopelovich L, Mehta RR, Christov K, Kelloff GJ, Steele VE, Pezzuto JM. (2001) Induction of atypical ductal hyperplasia in mouse mammary gland organ culture. J Natl Cancer Inst. 93:1103-1106.
    [ PubMed Abstract ]
  • Newmark HL, Yang K, Lipkin M, Kopelovich L, Liu Y, Fan K, Shinozaki H. (2001) A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis. 22:1871-1875.
    [ PubMed Abstract ]
  • Rodriguez-Burford C, Lubet RA, Steele VE, Eto I, Bandy M, Juliana MM, Weiss HL, Grizzle WE, Kelloff GJ, Grubbs CJ. (2001) Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. Oncol Rep. 8:373-379.
    [ PubMed Abstract ]
  • Sharma S, Ghoddoussi M, Gao P, Kelloff GJ, Steele VE, Kopelovich L. (2001) A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res. 21:3829-3837.
    [ PubMed Abstract ]
  • Sun SY, Yue P, Kelloff GJ, Steele VE, Lippman SM, Hong WK, Lotan R. (2001) Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev. 10:595-601.
    [ PubMed Abstract ]
  • Wang Y, Hu L, Yao R, Wang M, Crist KA, Grubbs CJ, Johanning GL, Lubet RA, You M. (2001) Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor. Oncogene. 20:7710-7721.
    [ PubMed Abstract ]
  • Weiss HL, Urban DA, Grizzle WE, Cronin KA, Freedman LS, Kelloff GJ, Lieberman R. (2001) Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer. Urology. 57:220-223.
    [ PubMed Abstract ]
  • Zujewski J, Vaughn-Cooke A, Flanders KC, Eckhaus MA, Lubet RA, Wakefield LM. (2001) Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Res. 3:66-75.
    [ PubMed Abstract ]

2000

  • Arif JM, Gairola CG, Kelloff GJ, Lubet RA, Gupta RC. (2000) Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. Mutat Res. 452(1):11-18.
    [ PubMed Abstract ]
  • Boone CW, Kelloff GJ. (2000) Endpoint markers for cancer chemoprevention trials derived from the lesion of precancer (intraepithelial neoplasia) measured by computer-assisted quantitative image analysis. J Cell Biochem Suppl. 34:67-72. Review.
    [ PubMed Abstract ]
  • Boone CW, Stoner GD, Bacus JV, Kagan V, Morse MA, Kelloff GJ, Bacus JW. (2000) Chemoprevention with theaflavins of rat esophageal intraepithelial neoplasia quantitatively monitored by image tile analysis. Cancer Epidemiol Biomarkers Prev. 9(11):1149-54.
    [ PubMed Abstract ]
  • Boone CW, Stoner GD, Bacus JV, Kagan V, Morse MA, Kelloff GJ, Bacus JW. (2000) Quantitative grading of rat esophageal carcinogenesis using computer-assisted image tile analysis. Cancer Epidemiol Biomarkers Prev. 9(5):495-500.
    [ PubMed Abstract ]
  • Cho KH, Pezzuto JM, Bolton JL, Steele VE, Kelloff GJ, Lee SK, Constantinou A. (2000) Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur J Cancer. 36(16):2146-56.
    [ PubMed Abstract ]
  • Chow HH, Earnest DL, Clark D, Mason-Liddil N, Kramer CB, Einspahr JG, Guillen-Rodriguez JM, Roe DJ, Malone W, Crowell JA, Alberts DS. (2000) Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev. 9(4):351-6.
    [ PubMed Abstract ]
  • Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, Kelloff G, Lubet R. (2000) Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole. Breast Cancer Res Treat. 60(2):117-28.
    [ PubMed Abstract ]
  • D'Agostini F, Balansky R, Pesce C, Fiallo P, Lubet RA, Kelloff GJ, De Flora S. (2000) Induction of alopecia in mice exposed to cigarette smoke. Toxicol Lett. 114(1-3):117-23.
    [ PubMed Abstract ]
  • D'Ambrosio,S.M., D'Ambrosio,R.G., Milo,G.E., Casto,B.C., Kelloff,G.J., Steele,V.E. (2000) Differential responses of normal, premalignant, and malignant human oral epithelial cells by chemopreventive agents. AntiCancer Research 20(4): 2273-2280.
    [ PubMed Abstract ]
  • Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolo G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone WF, Bruzzi P. (2000) Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev. Oct;9(10):1071-8.
    [ PubMed Abstract ]
  • Elmore E, Luc TT, Li HR, Buckmeier JA, Steele VE, Kelloff GJ, Redpath JL. (2000) Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data. Anticancer Res. 20(1A):27-32.
    [ PubMed Abstract ]
  • Elmore E, Luc TT, Steele VE, Kelloff GJ, Redpath JL. (2000) The human epithelial cell cytotoxicity assay for determining tissue specific toxicity. Methods Cell Sci 22(1):17-24.
    [ PubMed Abstract ]
  • Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60(20):5599-5602.
    [ PubMed Abstract ]
  • Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. Mar 15;92(6):486-92.
    [ PubMed Abstract ]
  • Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA.(2000) Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp Lung Res. 26(8):757-72.
    [ PubMed Abstract ]
  • Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, Donehower LA, Jacoby RF, Dove WF. (2000) Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A. 97(7):3461-6.
    [ PubMed Abstract ]
  • Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60(18):5040-4.
    [ PubMed Abstract ]
  • Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. (2000) Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 21(7):1271-9.
    [ PubMed Abstract ]
  • Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA. (2000) Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 60(7):1864-70.
    [ PubMed Abstract ]
  • Kelloff GJ. (2000) Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 78:199-334.
    [ PubMed Abstract ]
  • Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 130(2S Suppl):467S-471S. Review.
    [ PubMed Abstract ]
  • Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. (2000) Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 9(2):127-37. Review.
    [ PubMed Abstract ]
  • Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M (2000) Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21(1):113-6.
    [ PubMed Abstract ]
  • Lawrence JA, Malpas PB, Sigman CC, Kelloff GJ. (2000) Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. J Cell Biochem Suppl. 34:103-14. Review.
    [ PubMed Abstract ]
  • Liu J, Gu P, Bergman G, Kelloff GJ, Boone CW, You M, Wang Y. (2000) Detection of genetic alterations in mouse lung adenocarcinomas by two-dimensional gel electrophoresis. Exp Lung Res. 26(8):651-8.
    [ PubMed Abstract ]
  • Liu Y, Kyle E, Lieberman R, Crowell J, Kelloff G, Bergan RC. (2000) Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1- integrin complex formation. Clin Exp Metastasis.18(3):203-12.
    [ PubMed Abstract ]
  • Lantry LE, Zhang Z, Crist KA, Wang Y, Hara M, Zeeck A, Lubet RA, You M. (2000) Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp Lung Res. 26(8):773-90.
    [ PubMed Abstract ]
  • Lubet RA, Zhang Z, Wiseman RW, You M. (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res. 26(8):581-93. Review.
    [ PubMed Abstract ]
  • Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60(2):293-7.
    [ PubMed Abstract ]
  • Reddy BS, Hirose Y, Lubet RA, Steele VE, Kelloff GJ, Rao CV. (2000) Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. Int J Mol Med. 5(4):327-30.
    [ PubMed Abstract ]
  • Shilkaitis A, Green A, Steele V, Lubet R, Kelloff G, Christov, K. (2000) Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. Carcinogenesis 21(2):227-233.
    [ PubMed Abstract ]
  • Shilkaitis, A., Graves, J., Mehta, R., Hu, L., You, M., Lubet, R., Steele, V., Kelloff, G., Christov, K. (2000) Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. Cell Growth & Differentiation 11:437-445.
    [ PubMed Abstract ]
  • Singletary E, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, Colchin M, Bevers T, Stelling C, Fornage B, Fritsche H, Hittelman W, Kelloff G, Lippman SM. (2000) Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomarkers Prev. 9(10):1087-90.
    [ PubMed Abstract ]
  • Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., Sigman, C.C., and Kelloff, G.J. (2000) Potential use of lipoxygenase inhibitors for cancer chemopreventions. Exp. Opin. Invest. Drugs 9(9):2121-2138.
  • Steele VE, Kelloff GJ, Balentine D, Boone CW, Mehta R, Bagheri D, Sigman CC, Zhu S, Sharma S. (2000) Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis 21(1):63-67.
    [ PubMed Abstract ]
  • van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT (2000) Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 6(1):78-89.
    [ PubMed Abstract ]
  • Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, Woods J, Price R, Gray K, Kelloff GJ. (2000) Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21(6):1149-55.
    [ PubMed Abstract ]
  • Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ. (2000) Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 21(2):179-182.
    [ PubMed Abstract ]
  • Yang K, Lamprecht SA, Liu Y, Shinozaki H, Fan K, Leung D, Newmark H, Steele VE, Kelloff GJ, Lipkin M. (2000) Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 21(9):1655-60.
    [ PubMed Abstract ]
  • Zhang Z, Liu Q, Lantry LE, Wang Y, Kelloff GJ, Anderson MW, Wiseman RW, Lubet RA, You M. (2000) A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res. 60(4):901-7.
    [ PubMed Abstract ]

1999

  • Arbeit JM, Riley RR, Huey B, Porter C, Kelloff G, Lubet R, Ward JM, Pinkel D. (1999) Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice. Cancer Res 59(15):3610-20.
  • Bacus JW, Boone CW, Bacus JV, Follen M, Kelloff GJ, Kagan V, Lippman SM. (1999) Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev 8(12):1087-94.
  • Bednarek A; Shilkaitis A; Green A; Lubet R; Kelloff G; Christov K; Aldaz CM (1999) Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis 20:879-83.
  • Brown AP, Morrissey RL, Crowell JA, Levine BS. (1999) Thirteen-week oral toxicity study of difluoromethylornithine in combination with tamoxifen citrate in female dogs. Cancer Chemother Pharmacol. 43(6):479-88.
  • Brown AP, Morrissey RL, Crowell JA, Levine BS. (1999) Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study. Cancer Chemother Pharmacol. 44(6):475-83.
  • Cohen LA, Zhao Z, Pittman B, Lubet, R. (1999) S-allylcysteine, a garlic constituent, fails to inhibit N-methylnitrosourea-induced rat mammary tumorigenesis. Nutr Cancer 35(1):58-63.
  • Cronin KA, Freedman LS, Lieberman R, Weiss HL, Beenken SW, Kelloff GJ. (1999) Bayesian monitoring of phase II trials in cancer chemoprevention. J Clin Epidemiol 2(8):705-11.
  • Elmore, E.E., Sun, C., Li, H-R., Wyatt, G.P., Buckmeier, J.A., Steele, V.E., Kelloff, G.J., and Redpath, L. (1999) In vitro chemopreventive efficacy screening using human keratinocytes and the in vivo data correlation. Anticancer Res. 19:909-918.
  • Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25(4):231-40.
  • Haag JD; Brasic GM; Shepel LA; Newton MA; Grubbs CJ; Lubet RA; Kelloff GJ; Gould MN (1999) A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors. Mol Carcinog 24:47-56.
  • Hawk E, Lubet R, Limburg, P (1999) Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(8 Suppl):1731-43.
  • Hawk E, Lubet R, Limburg P (1999) Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63.
  • Izzotti A, Bagnasco M, D'Agostini F, Cartiglia C, Lubet RA, Kelloff GJ, De Flora S. (1999) Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. Carcinogenesis 20(8):1499-506.
  • Izzotti A, Camoirano A, Cartiglia C, Grubbs C, Lubet R, Kelloff G, and DeFlora S. (1999) Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. Cancer Res. 59:4285-4290.
  • Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao C, and Reddy BS. (1999) Chemopreventive effect of curcumin, a naturally-occurring antiinflammatory agent during the promotion/progression stages of colon cancer. Cancer Res., 59:597-601.
  • Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC. (1999) Progress in cancer chemoprevention. Ann N Y Acad Sci. 889:1-13. Review.
  • Kelloff, GJ, Lieberman, R, Steele, VE, Boone, CW, Lubet, RA, Kopelovich, L, Malone, WA, Crowell, JA, Sigman, CC. (1999) Chemoprevention of prostate cancer: concepts and strategies. Eur. Urol 35:342-350.
  • Kelloff GJ, Sigman CC, Greenwald P. (1999) Cancer chemoprevention: progress and promise. Eur J Cancer. Dec;35(13):1755-62. Review.
  • Kirchner DL, Mercieca MD, Crowell JA, Levine BS. (1999) Developmental toxicity studies of 2-(difluoromethyl)-dl-ornithine (DFMO) in rats and rabbits. Toxicol Sci. Jul;50(1):127-35.
  • Kopelovich L, Henson DE, Gazdar AF, Dunn B, Srivastava S, Kelloff GJ, Greenwald P. (1999) Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. Clin Cancer Res 5(12):3899-905.
  • Lam S, leRiche JC, Zheng Y; Coldman A; MacAulay C; Hawk E; Kelloff G; Gazdar AF (1999) Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 91:691-6.
  • Lantry LE; Zhang Z; Crist KA; Wang Y; Kelloff GJ; Lubet RA; You M (1999) 5-Aza-2'- deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1- (3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 20:343-6.
  • Lee, S.K., Song, L., Mata-Greenwood, E., Kelloff, G.J., Steele, V.E., and J.M. Pezzuto (1999) Modulation of in vitro biomarkers of the carcinogenic process by chemopreventive agents. Anticancer Res. 19:35-44.
  • Li H, Kramer PM, Lubet RA, Steele VE, Kelloff GJ, Pereira MA (1999) Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett 147(1-2):187-93.
  • Li, H., Schut, H.A.J., Conran, P., Kramer, P.M., Lubet, R.A., Steele, V.E., Hawk, E.E., Kelloff, G.J., and Pereira, M.A. (1999) Prevention by aspirin and its combination with -difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20(3):425-430.
  • McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM (1999) National Cancer Institute--supported cancer chemoprevention research:coming of age. J Clin Oncol 1999 Nov;17(11 Suppl):53-62.
  • McCormick, D.L., Rao, K.V.N., Steele, V.E., Lubet, R.A., Kelloff, G.J., and Bosland M.C. (1999) Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 59: 521-524.
  • Rao KV; Johnson WD; Bosland MC; Lubet RA; Steele VE; Kelloff GJ; McCormick DL (1999) Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 59:3084-9.
  • Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV. (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 15;59(14):3387-91.
  • Reddy BS, Kawamori T, Lubet R, Steele V, Kelloff G, Rao CV. (1999) Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis 20(8):1645-8.
  • Rodriguez-Burford, C., Lubet, R.A., Eto, I., Juliana, M.M., Kelloff, G.J., Grubbs, C.J., and Steele, V.E. (1999) Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea (MNU)- induced mammary cancer model. Carcinogenesis 20(1):71-76.
  • Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. (1999) Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20(2):185-91.
  • Sneige N; Lagios MD; Schwarting R; Colburn W; Atkinson E; Weber D; Sahin A; Kemp B; Hoque A; Risin S; Sabichi A; Boone C; Dhingra K; Kelloff G; Lippman S (1999) Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 30:257-62.
  • Steele, V.E., Bagheri, D. Balentine, D.A., Boone, C.W., Mehta, R., Morse, M.A., Sharma, S., Sigman, C.C., Stoner, G.D., Wargovich, M.J., Weisburger, J.H., Zhu, S., and Kelloff, G.J. (1999) Preclinical efficacy studies of green and black tea extracts. Fed. Proc. Exp. Biol. 220:210-212
  • Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., Sigman, C.C., and Kelloff, G.J. (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiology, Biomarkers, and Prevention 8:467-483.
  • Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RU. (1999) Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 470:45-53.
  • Urban D; Myers R; Manne U; Weiss H; Mohler J; Perkins D; Markiewicz M; Lieberman R; Kelloff G; Marshall M; Grizzle W (1999) Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 35:429-38.
  • Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. Nov 3;91(21):1847-56.
    [PubMed Abstract]
  • White, E.L., Ross, L.J., Steele, V.E., Kelloff, G.J., and D.L. Hill. (1999) Screening of cancer preventive chemicals as aromatase inhibitors in vitro. Anticancer Res. 19:1017-1020.
  • Zheng, Y., Kramer, P.M., Lubet, R.A., Steele, V.E., Kelloff, G.J., and Pereira, M.A. (1999) Effects of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis, and aberrant crypt foci. Carcinogenesis 20(2):255-260.

1998

  • Arif JM; Gairola CG; Glauert HP; Kelloff GJ; Lubet RA; Gupta RC (1998) Inhibition of cigarette smoke-related lipophilic DNA adducts in rat tissues by dietary oltipraz. Carcinogenesis 19:1515-7.
  • Berton TR; Conti CJ; Mitchell, DL; Aldaz CM; Lubet RL; Fischer SM. (1998) The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Molecular Carcinogenesis 23: 175-184.
  • Boone CW, Kelloff, GJ. (1998) Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis. Cancer Surv 32:133-47.
  • Boone, C.W., Steele, V.E., Gaylor, D., and Kelloff, G.K. (1998) Use of Druckrey analysis to quantitatively evaluate the chemopreventive efficacy of N-difluoro-methylornithine (DFMO), aprototype proliferation inhibitor. Mutation Res. 402:173-177.
  • Chi WJ; Doong SL; Lin-Shiau SY; Boone CW; Kelloff GJ; Lin JK (1998) Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. Carcinogenesis 19:2133-8.
  • Conaway, C.C., Chung, F.L., Rivenson, A., Steele, V.E., Kelloff, G.J., Jiao, D(1998) Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett 124(1):85-93.
  • Kelloff, G.J., Sigman, C.C., Boone, C.W., Hawk, E.T., Crowell, J.A., Steele, V.E., Eisenhauer, K., Lieberman, R., Lubet, R.A. (1998) Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 7(1):65-78.
  • Li, H., Pereira, M.A., Kelloff, G.J., Steele, V.E., Lubet, R.A., Kramer, P.M. (1998) Effect of calcium on azoxymethane-induced aberrant crypt foci and cell proliferation in the colon of rats. Cancer Lett 124(1):39-46.
  • Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. (1998) Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2):420-7.
  • Lubet, R.A., Moon, R.D., Thomas, C.F., Kelloff, G.J., Steele, V.E., Grubbs, C.J., Wang, Y., You, M., Lei, X.D. Prough, R.A., Gordon, G.B. (1998) Modulation of methylnitrosourea-induced breast cancer in Sprague-Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res Mar 1;58(5):921-6.
  • Lubet, R.A., Steele, V.E., DeCoster, R., Bowden, C., You, M., Juliana, M.M., Eto, I., Kelloff, G.J., Grubbs, C.J. (1998) Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 19(8):1345-1351.
  • McCormick, D.L., Rao, K.V.N., Dooley, L., Steele, V.E., Lubet, R.A., and Kelloff, G.J., and Bosland, M.C. (1998) Influence of N-methyl-N-nitrosourea, testosterone, and N-(4- hydroxyphenyl)-all-trans-retinamide on prostate cancer in Wistar-Unilever rats. Cancer Research 58:3282-3288.
  • Negrusz A, Moore CM, McDonagh NS, Woods EF, Crowell JA, Levine BS. (1998) Determination of phenethylamine, a phenethyl isothiocyanate marker, in dog plasma using solid-phase extraction and gas chromatography-mass spectrometry with chemical ionization. J Chromatogr B Biomed Sci Appl. Oct 23;718(1):193-8.
  • Pezzuto, J.M. and Steele, V.E. (eds.) (1998) Exploring the Power of Phytochemicals: Research Advances on Grape Compounds. Pharmaceutical Biology. Volume 36. Swets and Zeitlinger, Lisse, Netherlands.
  • Prashad, R., Sanford, K.K., Price, F.M., Steele, V.E., Tarone, R.E., Kelloff, G.J., and Boone, C.W. (1998) Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells. AntiCancer Res 18:3263-3266.
  • Ruffin MT 4th, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, Crowell J, Kelloff G, Boland CR, Brenner DE. (1998) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997 Aug 6;89(15):1152-60.
  • Sabourin CL; Wang QS; Ralston SL; Evans J; Coate J; Herzog CR; Jones SL; Weghorst CM; Kelloff GJ; Lubet RA; You M; Stoner GD (1998) Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. Exp Lung Res 24:499-521.
  • Steele, V.E., Boone, C.W., Lubet, R.A., Crowell, J.A., Holmes, C.A., Sigman, C.C., and Kelloff, G.J. (1998) Preclinical drug development paradigms for chemopreventives. Hematology/Oncology Supplement 12(5):943-961.
  • Steele, V.E., Wyatt, G.P., Kelloff, G.J., and E. Elmore. 1998. Differential growth response to exogenous calcium in normal and carcinogen-exposed primary human keratinocyte cell cultures. Anticancer Res 18(6):4067-4070.
  • Steele, V.E., Wargovich, M.J., McKee, K., Sharma, S., Wilkinson, B.P., Wyatt, G.P., Gao, P., and Kelloff, G.J. 1998. Cancer chemoprevention drug development strategies for resveratrol. Pharmaceutical Biology 36(3): 1-7
  • Thompson, H.J., McGinley, J.N., Wolfe, P., Steele, V.E., Kelloff, G.J., and Singh, M. 1998. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis 19(12): 2181-2185.
  • Weisburger, J.H., Zang, E., Pittman, B., Balentine, D.A., Steele, V.E., Boone, C..W., Kelloff, G.J., Reinhardt, J., Aliaga, C., Rivenson, A. (1998) Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer. Proc Soc Exp Biol Med 217(1):104-8.
  • White, E.L., Hill, D.L., Kelloff, G.J., Steele, V.E., Ross, L.J. (1998)Screening of potential cancer preventing chemicals as antioxidants in an in vitro assay Anticancer Res 18(2A):769-73.
  • White, E.L., Hill, D.L., Steele, V.E., Kelloff, G.J., Schmid, S.M., Ross, L.J. (1998)Screening of potential cancer-preventing chemicals for inhibition of induction of ornithine decarboxylase in epithelial cells from rat trachea.Oncol Rep 5(3):717-22.
  • White, E.L., Hill, D.L., Steele, V.E., Kelloff, G.J., Schmid, S.M., Ross, L.J. (1998) Screening of potential cancer preventing chemicals for induction of glutathione in rat liver cells. Oncol Rep 5(2):507-12.

1997

  • Arnold, J.T., Wilkinson, B.P., Sharma, S., and Steele, V.E. (1997) Chemoprevention of carcinogen-induced transformation in primary rat tracheal epithelial cells. Methods in Cell Science 19(1): 3-8.
  • Bacus, J.W., Boone, C.W., Kelloff, G.J., Moon, R.C., Stoner, G.D., Bacus, J.V. (1997) Quantitation of preinvasive neoplastic progression in animal models of chemical carcinogenesis. J Cell Biochem Suppl;28-29:21-38.
  • Boone, C.W., Kelloff, G.J., Steele, V.E., Bacus, J.V., Bacus, J.W. (1997) Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents. J Cell Biochem Suppl;28-29:1-20.
  • Boone, C.W., Kelloff, G.J. (1997): Biomarker end-points in cancer chemoprevention trials. IARC Sci Publ;(142):273-80.
  • Boone, C.W., Kelloff, G.J., Steele, V.E., Bacus, J.V., Bacus, J.W. (1997) Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials. Proc Soc Exp Biol Med 216(2):151-65.
  • Boiko, I.V., Hittelman, W.N., Atkinson, E.N., Boone, C.W., Nishioka, K., Malpica, A., Hu, W., White, R.A., Pandey, D.K., Mitchell, M.F. (1997) DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 6(10):849-55.
  • Crist, K.A., You, M, Kelloff, G.J., Steele, V.E., Lubet, R.A., Wang Y (1997)Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis. J Cell Biochem Suppl;27:92-9.
  • Crowell, J.A., Kelloff, G.J., Hall, L.B., Goldenthal, E.I., Heath, J.E., Rodman, L.E., Page, J.G. (1997) Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Fundam Appl Toxicol 35(1):9-21.
  • Duewer DL, Thomas JB, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. (1997) NIST/NCI Micronutrients Measurement Quality Assurance Program: measurement repeatabilities and reproducibilities for fat-soluble vitamin-related compounds in human sera. Anal Chem. Apr 1;69(7):1406-13.
  • Elmore, E., Sun, C., Li, H-R, Wyatt, G.P., Buchmeier, J.A., Steele, V.E, and Redpath, J.L. (1997) The human epidermal cell assay for chemopreventive agents. Methods in Cell Science 19(1): 13-18.
  • Herzog, C.R., You, M., Lubet, R.A. (1997)Genetic alterations in mouse lung tumors: implications for cancer chemoprevention.J Cell Biochem Suppl 28-29:49-63.
  • Hirsch, F.R., Mulshine, J.L., Pastorino, U., Linnoila, R.I., Kelloff, G.J., Gritz, E., Gray, N., Brambilla, E. (1997 ) Prevention and early detection of lung cancer-clinical aspects. Lung Cancer 17(1):163-74.
  • Hu, L., Wang, Y., You, M., Lubet, R.A., Steele, V.E., Kelloff, G.J., Crist, K.A., Lin L (1997) Detection of differentially expressed genes in methylnitrosourea-induced rat mammary adenocarcinomas. J Cell Biochem Suppl;28-29:117-24.
  • Jang, M-S. and Pezzuto, J.M. (1997) Assessment of cyclooxygenase inhibitors using in vitro assay systems. Methods in Cell Science 19(1): 25-31.
  • Kelloff, G.J., Lubet, R.A., Fay, J.R., Steele, V.E., Boone, C.W., Crowell, J.A., and Sigman, C.C. (1997) Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiology Biomarkers & Prevention 6: 267-282.
  • Kelloff, G.J., Hawk, E.T., Karp, J.E., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A and Sigman, C.C. (1997) Progress in Clinical Chemoprevention. Semin. Oncol. 24 (2): 241-252.
  • Kelloff, G.J., Sigman, C.C., Lubet, R.A., Steele, V.E., Hawk, E.T., Nayfield, S.G., Crowell, J.A., Boone, C.W. (1997) Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res;396:159-83.
  • Lantry, L.E., You, M., Lubet, R.A., Kelloff, G.J., Wang, Y., Crist, K.A., Gao, F., Zhang, Z. (1997)Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung. J Cell Biochem Suppl;27:20-5.
  • Lubet, R.A., Steele, V.E., Eto, I., Juliana, M., Kelloff, G., and Grubbs, C.J. (1997) Chemopreventive efficacy of anethole trithione, N-acetyl-l-cysteine, miconazole, and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Int J. Cancer 72:1-7.
  • Matzinger, S.A., You, M., Lubet, R.A., Kelloff, G.K., Stoner, G.D., Crist, K.A., Wang, Y., Chen, B. (1997) Tissue-specific expression of the K-ras allele from the A/J parent in (A/J x TSG-p53) F1 mice. Gene 188(2):261-9.
  • Mehta, R.G., Hawthorne, M.E., and Steele, V.E. (1997) Induction and prevention of carcinogen-induced precancerous lesions in mouse mammary gland organ culture. Methods in Cell Science 19(1): 19-24.
  • Mehta, R.G., Steele, V.E., Pierson, H., Constantinou, A., and Moon, R.C. 1997. Licorice: Absorption, distribution, metabolism and cancer prevention. In: Lachance P.A. (ed.) Nutriceuticals: Designer Foods III Garlic, Soy, and Licorice, Trumbull, CT: Food and Nutrition Press, Inc., pp265-278.
  • Morse, M.A., Stoner, G.D., Harbowy, M.E., Balentine, D.A., Boone, C.W., Kelloff, G.J., Steele, V.E., Kresty, L.A. (1997) Effects of theaflavins on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis. Nutr Cancer;29(1):7-12.
  • Rao, C.V., Reddy, B.S., Steele, V., Kelloff, G., Lubet, R., Simi, B., Wang, C.X. (1997 ) Enhancement of experimental colon cancer by genistein.Cancer Res 57(17):3717-22.
  • Reddy, B.S., Rao, C.V., Kelloff, G.J., Steele, V.E., Lubet, R., Samaha H; Wang CX (1997 ) Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 57(3):420-5.
  • Ruffin, M.T.4th, Brenner, D.E., Boland, C.R., Kelloff, G., Crowell, J., Peters-Golden, M., Vaerten, M.A., Normolle, D., Rock, C.L., Krishnan, K. (1997 ) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89(15):1152-60.
  • Samaha, H.S., Kelloff, G.K., Steele, V.E., Rao, C.V., and Reddy, B.S. (1997) Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Research 57: 1301-1305.
  • Sharma, S., Nemecz, S. K., Zhu, S. and Steele, V.E. (1997) Identification of chemopreventive agents by screening for induction of glutathione-S-transferase as a biomarker. Methods in Cell Science 19(1): 49-52.
  • Sharma, S., Pennington, L.P. and Steele, V.E. (1997) Induction of NADPH-quinone reductase as a screening assay for potential chemopreventive agents. Methods in Cell Science 19(1):63-66.
  • Sharma, S., Stutzman, J.D., Garris, K.R., and Steele, V.E. (1997) An ornithine decarboxylase activity assay to screen for potential chemopreventive agents. Methods in Cell Science 19(1):33-36.
  • Sharma, S., Wilkinson, B.P., and Steele, V.E. (1997) Development of glutathione induction as a screening assay for potential chemopreventive agents. Methods in Cell Science 19(1):53-56.
  • Sharma, S., Wyatt, G.P., Elmore, E., and Steele,V.E. (1997) The A427 anchorage-independence assay as a screening tool to identify potential chemopreventive agents. Methods in Cell Science 19(1): 9-12.
  • Sharma, S., Wyatt, G.P., and Steele, V.E. (1997) A carcinogen -DNA binding assay as a biomarker screen for identifying potential chemopreventive agents. Methods in Cell Science 19(1): 45-48.
  • Steele, V.E. (ed.) (1997) Methods in Cell Science. In Vitro Methods to Screen Chemopreventive Agents. Volume 19. Kluwer Academic Publishers, Dordrecht, Netherlands.
  • Steele, V.E., Boone, C.W., Lubet, R.A., Sigman, C.C., and Kelloff, G.J. (1997) Rationale for the selection and use of in vitro assays to screen for chemopreventive agents. Methods in Cell Science 19(1):1-2.
  • Stoner, G.D., Kelloff, G.J., Morse, M.A. (1997) Perspectives in cancer chemoprevention. Environ Health Perspect 105 Suppl 4:945-54.
  • Wattenberg, L.W., Kelloff, G.J., Steele, V.E., Zimmerman, C.L., Estensen, R.D., Wiedmann, T.S. (1997 ) Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res Dec 15;57(24):5489-92.
  • Zheng, Y., Pereira, M.A., Kelloff, G.J., Steele, V.E., Lubet, R.A., Olson G; Kramer PM (1997) Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis Nov;18(11):2119-25.

1996

  • Burney, K.D., Krishnan, K., Ruffin, M.T., Zhang, D. and Brenner, D.E. (1996) Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Arch. Fam. Med. 5: 297-300.
  • Chung, F.-L., Kelloff, G., Steele, V., Pittman, B., Zang, E., Jiao, D., Rigotty, J., Choi, C.-I. and Rivenson, A. (1996) Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Cancer Res. 56: 772-778.
  • Crist, K.A., Kim, K., Goldblatt, P.J., Boone, C.W., Kelloff, G.J., and You, M. (1996) DNA quantitation in cervical intraepithelial neoplasia thick tissue sections by confocal laser scanning microscopy. J. Cell. Biochem. Suppl. 25: 49-56.
  • Dimitrov NV, Meyer-Leece C, McMillan J, Gilliland D, Perloff M, Malone W. (1996) Plasma alpha-tocopherol concentrations after supplementation with water- and fat-soluble vitamin E. Am J Clin Nutr. Sep;64(3):329-35.
    [PubMed Abstract]
  • Gould, M.N., Lubet, R.A., Kelloff, G.J. and Haag, J.D. (1996) Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis. J. Cell. Biochem. Suppl. 25: 37-40.
  • Greenwald, P. and Kelloff, G.J. (1996) The role of chemoprevention in cancer control. Principles of Chemoprevention, IARC Scientific Publication No. 139, Lyon, France: International Agency for Research on Cancer, pp. 13-23.
  • Hawk, E., Kelloff, G., Prindiville, S. (1996) NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 110(2):654-5.
  • Hellriegel, E.T., Kong, A.N., Lubet, R.A., Nims, R.W., Dragnev, K.H., Fei, P., Matwyshyn, G.. (1996) Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. Biochem Pharmacol Nov 22;52(10):1561-8.
  • Jacoby, R.F., Marshall, D.J., Newton, M., Novakovic, K., Tutsch, K., Cole, C.E., Lubet, R.A., Kelloff, G.J., Verma, A., Moser, A.R. and Dove, W.S. (1996) Chemoprevention of spontaneous intestinal adenomas in the ApcMIN model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res. 56: 710-714.
  • Karp, J.E., Chiarodo, A., Brawley, O. and Kelloff, G.J. (1996) Prostate cancer prevention: Investigational approaches and opportunities. Cancer Res. 56: 5547-5556.
  • Kelloff, G.J. and Boone, C.W. (eds.) (1996) Cancer Chemopreventive Agents: Drug Development Status and Future Prospects III, J. Cell. Biochem. (Suppl. 26), New York, NY: Wiley-Liss.
  • Kelloff, G.J. and Boone, C.W. (eds.) (1996) Prospects for Chemoprevention in Cohorts with Cancer Risk Markers, J. Cell. Biochem. (Suppl. 25), New York, NY: Wiley-Liss.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Nayfield, S.G., Hawk, E., Malone, W.F., Steele, V.E., Lubet, R.A. and Sigman, C.C. (1996) Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem. Suppl. 25: 1-14.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R.A., Doody, L.A., Malone, W.F., Hawk, E.T. and Sigman, C.C. (1996) New agents for cancer chemoprevention. J. Cell. Biochem. Suppl. 26: 1-28.
  • Kelloff, G.J., Boone, C.W., Sigman, C.C. and Greenwald, P. (1996) Chemoprevention of colorectal cancer. In: Young, G.P., Levin, B. and Rozen, P. (eds.) Prevention and Early Detection of Colorectal Cancer: Principles and Practice, London, England: W.B. Saunders, pp. 115-139.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Crowell, J.A., Lubet, R.A., Greenwald, P., Hawk, E.T., Fay, J.R. and Sigman, C.C. (1996) Mechanistic considerations in the evaluation of chemopreventive data. Principles of Chemoprevention, IARC Scientific Publication No. 139, Lyon, France: International Agency for Research on Cancer, pp. 203-221.
  • Kelloff, G.J., Fay, J.R., Steele, V.E., Lubet, R.A., Boone, C.W., Crowell, J.A. and Sigman, C.C. (1996) Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev. 5: 657-666.
  • Kelloff, G.J., Hawk, E.T., Crowell, J.A., Boone, C.W., Nayfield, S.G., Perloff, M., Steele, V.E., Lubet, R.A and Sigman, C.C. (1996) Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 10: 1471-1484.
  • Kelloff, G.J., Sigman, C.C., Lubet, R.A., Steele, V.E., Boone, C.W., Crowell, J.A., Hawk, E.T. (1996) Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 5 Suppl 2:79-85.
  • Kensler, T.W. and Groopman, J.D. (1996) Carcinogen-DNA and protein adducts: Biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. J. Cell. Biochem. Suppl. 25: 85-91.
  • Korytynski, E.A., Kelloff, G.J., Suk, W.A., Sharma, A. and Elmore, E. (1996) The development of an anchorage-independence assay using human lung tumor cells to screen potential chemopreventive agents. Anticancer Res. 16: 1091-1094.
  • Liu, J., Wang, Y., Gu, P., Patrick, J., Crist, K.A., Sabourin, C., Stoner, G.D., Mitchell, M.F., Fanning, J.D., Kim, K., Goldblatt, P.J., Kelloff, G.J., Boone, C.W. and You, M. (1996) Detection of genomic alterations in human cervical cancer by two-dimensional gel electrophoresis. J. Cell. Biochem. Suppl. 25: 41-48.
  • McCormick, D.L., Johnson, W.D., Rao, K.V.N., Bowman-Gram, T., Steele, V.E., Lubet, R.A. and Kelloff, G.J. (1996) Chemoprevention of lymphoma development in PIM transgenic mice by N-(4-hydroxyphenyl)retinamide and -difluoromethylornithine. Carcinogenesis 17: 2513-2518.
  • McCormick, D.L., Rao, K.V.N., Johnson, W.D., Bowman-Gram, T.A., Steele, V.E., Lubet, R.A. and Kelloff, G.J. (1996) Exceptional chemopreventive activity of low dose dehydroepiandrosterone in the rat mammary gland. Cancer Res. 56: 1724-1726.
  • Mitchell, M.F., Morrow, P.C., Boone, C.W. and Kelloff, G.J. (eds.) (1996) Cancer Chemoprevention: Cervix, Endometrium and Ovary. J. Cell. Biochem. (Suppl. 23), New York, NY: Wiley-Liss.
  • Pereira, M.A., Barnes, L.H., Steele, V.E., Kelloff, G.J. and Lubet, R.A. (1996) Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376.
  • Pereira, M.A., Grubbs, C.J., Barnes, L.H., Li, H., Olson, G.R., Eto, I., Juliana, M., Whitaker, L.M., Kelloff, G.J., Steele, V.E. and Lubet, R.A. (1996) Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz(a)anthracene-induced mammary cancer in rats. Carcinogenesis 17: 1305-1312.
  • Rao, C.V., Rivenson, A., Zang, E. Steele, V., Kelloff, G. and Reddy, B.S. (1996) Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res. 56: 3395-3398.
  • Rao, K.V.N., McCormick, D.L., Detrisac, C.J., Steele, V.E., Hawk, E.T. and Kelloff, G.J. (1996) Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17: 1435-1438.
  • Risio M., Lipkin, M., Newmark, H., Yang, K., Steele, V.E., Boone, C.W. and Kelloff, G.J. (1996) Apoptosis, cell replication and Western-style diet-induced tumorigenesis in mouse colon. Cancer Res. 56: 4910-4916.
  • Schottenfeld, D., Mitchell, M.F. and Hong, W.K. (1996) Screening and chemoprevention of gynecologic tumors. Obstet. Gynecol. Clin. North Am. 23: 285-294.
  • Steele, V.E., Sharma, S., Mehta, R., Elmore, E., Redpath, L., Rudd, C., Carter, C., Bagheri, D., Sigman, C.C., and Kelloff, G.J. (1996) Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell. Biochem. Suppl. 26: 29-53.
  • Wargovich, M.J., Chen, C-D., Jimenez, A., Steele, V.E., Velasco, M., Stephens, L.C., Price, R., Gray, K. and Kelloff, G.J. (1996) Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers & Prev. 5: 355-360.
  • Yang, K., Fan, K., Newmark, H., Leung,, D., Lipkin, M., Steele, V.E. and Kelloff, G.J. (1996) Cytokeratin, lectin, and acidic mucin modulation in differentiating colonic epithelial cells of mice after feeding Western-style diets. Cancer Res.56: 4644-4648.

1995

  • Anderson, L., Steele, V.K., Kelloff, G.J. and Sharma, S. (1995) Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver. J. Cell. Biochem. 22: 108-116.
  • Arnold, J.T., Wilkinson, B.P., Sharma, S. and Steele, V.E. (1995) Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay. Cancer Res. 55: 537-543.
  • Boone, C.W. and Kelloff, G.J. (1995) Biomarkers of premalignant breast disease and their use as surrogate endpoints in clinical trials of chemopreventive agents. The Breast J. 1: 228-235.
  • Cervantes, M., Zhou, H., Sahin, A., Dhingra, K., Valero, V., Ordonez, N., El-Naggar, A., Hess, K., Glassman, A. and Sen, S. (1995) p53 alterations show significant correlation with gene amplification and high S-phase index in breast cancer. Int. J. Oncol. 6: 955-962.
  • Dhingra, K. (1995) A Phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. J. Cell. Biochem. 23: 19-24.
  • Dragnev, K.H., Lubet, R.A., Nims, R.W. (1995) The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducer. Biochem Pharmacol 50(12):2099-104.
  • Greenwald P., Clifford, C., Pilch, S., Heimendinger, J. and Kelloff, G. (1995) New directions in dietary studies in cancer: The National Cancer Institute. In: Longnecker, J.B. (ed.) Nutrition and Biotechnology in Heart Disease and Cancer, New York, New York: Plenum Press, 229-239.
  • Greenwald, P., Kelloff, G.J., Boone, C.W. and McDonald, S.S. (1995) Genetic and cellular changes in colorectal cancer: Proposed targets of chemopreventive agents. Cancer Epidemiol. Biomark. Prev. 5: 691-702.
  • Greenwald, P., Kelloff, G., Burch-Whitman, C. and Kramer, B.S. (1995) Chemoprevention. CA A Cancer Journal for Clinicians 45: 31-49.
  • Grubbs, C.J., Steele, V.E., Casebolt, T., Juliana, M.M., Eto, I., Whitaker, L.M., Dragnev, K.H., Kelloff, G.J. and Lubet, R.L. (1995) Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res. 15: 709-716.
  • Gupta, E., Olopade, O.I., Ratain, M.J., Mick, R., Baker, T.M., Berezin, F.K., Benson, A.B., III and Dolan, M.E. (1995) Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin. Cancer Res. 1: 1133-1138.
  • Kelloff, G.J. and Boone, C.W. (eds.) (1995) Cancer Chemopreventive Agents: Drug Development Status and Future Prospects II, J. Cell. Biochem. (Suppl. 22), New York, NY: Wiley-Liss.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Nayfield, S.G., Hawk, E., Steele, V.E., Lubet, R.A. and Sigman, C.C. (1995) Development of breast cancer chemopreventive drugs. The Breast J. 1: 271-283.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Nayfield, S.G., Hawk, E., Steele, V.E., Lubet, R.A. and Sigman, C.C. (1995) Strategies for Phase II cancer chemoprevention trials: Cervix, endometrium, and ovary. J. Cell. Biochem. Suppl. 23: 1-9.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Fay, J.R. and Sigman, C.C. (1995) Inhibition of chemical carcinogenesis. In: Arcos, J., Argus, M. and Woo, Y. (eds.) Chemical Induction of Cancer: Modulation and Combination Effects, Boston, MA: Birkhäuser Boston, Inc., pp. 73-122.
  • Kelloff, G.J., Johnson, J.R., Crowell, J.A., Boone, C.W., DeGeorge, J.J., Steele, V.E., Mehta, M.U., Temeck, J.W., Schmidt, W.J., Burke, G., Greenwald, P. and Temple, R.J. (1995) Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomark. Prev. 4: 1-10.
  • Kensler, T.W. and Helzlsouer, K.J. (1995) Oltipraz: clinical opportunities for cancer chemoprevention. J. Cell. Biochem. Suppl. 22: 101-107.
  • Lubet, R.A., McCormick, D.M., Gordon, G.M., Grubbs, C., Lei, X.-D., Prough, R.A., Steele, V.E., Kelloff, G.J., Thomas, C.F. and Moon, R.C. (1995) Effects of dehydroepiandrosterone on MNU-induced breast cancer in Sprague-Dawley rats. Ann. N.Y. Acad. Sci. 774: 340-341.
  • Matzinger, S.A., Crist, K.A., Stoner, G.D., Anderson, M.W., Pereira, M.A., Steele, V.E., Kelloff, G.J., Lubet, R.A. and You, M. (1995) K-ras mutations in lung tumors from A/J and A/JxTSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis 16: 2487-2492.
  • Mitchell, M.F., Hittelman, W.N., Lotan, R., Nishioka, K., Tortolero-Luna, G., Richards-Kortum, R. and Hong, W.K. (1995) Chemoprevention trials in the cervix: Design, feasibility, and recruitment. J. Cell. Biochem. 23: 104-112.
  • Mitchell, M.F., Hittelman, W.K., Lotan, R., Nishioka, K., Tortolero-Luna, G., Richards-Kortum, R., Wharton, J.T. and Hong, W.K. (1995) Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer 76: 1956-1977.
  • Nishioka, K., Melgarejo, A.B., Lyon, R.R. and Mitchell, M.F. (1995) Polyamines as biomarkers of cervical intraepithelial neoplasia. J. Cell. Biochem. 23: 87-95.
  • Pendyala, L. and Creaven, P.J. (1995) Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent, during a Phase I trial. Cancer Epidemiol. Biomark. Prev. 4: 245-251.
  • Primiano, T., Egner, P.A., Sutter, T.R., Kelloff, G.J., Roebuck, B.D. and Kensler, T.W. (1995) Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res. 55: 4319-4324.
  • Rao, C.V., Rivenson, A., Kelloff, G.J. and Reddy, B.S. (1995) Chemoprevention of azoxymethane-induced colon cancer by ascorbylpalmitate, carbenoxolone, dimethylfumarate and p-methoxyphenol in male F344 rats. Anticancer Res. 15: 1199-1204.
  • Rao, C.V., Rivenson, A., Simi, B. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55: 259-266.
  • Rao, C.V., Rivenson, A., Simi, B., Zang, E., Hamid, R., Kelloff, G.J., Steele, V. and Reddy, B.S. (1995) Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate. Cancer Res. 55: 4311-4318.
  • Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V. and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55: 1464-1472.
  • Richter, F., Newmark, H.L., Richter, A., Leung, D. and Lipkin, M. (1995) Inhibition of Western-diet induced hyperproliferation and hyperplasia in mouse colon by two sources of calcium. Carcinogenesis 16: 2685-2689.
  • Schatzkin, A. and Kelloff, G. (1995) Chemo- and dietary prevention of colorectal cancer. Eur. J. Cancer 31A: 1198-1204.
  • Steele, V.E., Pereira, M.A., Sigman, C.C. and Kelloff, G.J. (1995) Cancer chemoprevention agent development strategies for genistein. J. Nutr. 125: 713S-716S.
  • Wargovich, M.J., Chen, C.D., Harris, C., Yang, E. and Velasco, M. (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int. J. Cancer 60: 515-519.

1994

  • Boone, C. W. and Kelloff, G.J. (1994) Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: Relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. J. Cell. Biochem. Suppl. 19: 10-22.
  • Boone, C.W. and Kelloff, G.J. (eds.) (1994) Quantitative Pathology in Chemoprevention Trials: Standardization and Quality Control of Surrogate Endpoint Biomarker Assays for Colon, Breast and Prostate, J. Cell. Biochem. (Suppl. 19), New York, NY: Wiley-Liss.
  • Crowell, J.A., Goldenthal, E.I., Kelloff, G.J., Malone, W.F. and Boone, C.W. (1994) Chronic toxicity studies of the potential cancer preventive 2-(difluoromethyl)-dl-ornithine. Fundam. Appl. Toxicol. 22: 341-354.
  • Kelloff, G.J. and Boone, C.W. (eds.) (1994) Cancer Chemopreventive Agents: Drug Development Status and Future Prospects I, J. Cell. Biochem. (Suppl. 20), New York, NY: Wiley-Liss.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. and Doody, L.A. (1994) Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials. J. Cell. Biochem. Suppl. 19: 1-9.
  • Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. and Sigman, C.C. (1994) Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol. Biomark. Prev. 3: 85-98.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Crowell, J.A., Lubet, R. and Sigman, C.C. (1994) Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 54: 2015s-2024s.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Fay, J.R., Lubet, R.A., Crowell, J.A. and Sigman, C.C. (1994) Mechanistic considerations in chemopreventive drug development. J. Cell. Biochem. Suppl. 20: 1-24.
  • Kelloff, G.J., Johnson, J.J., Crowell, J.A., Boone, C.W., DeGeorge, J.J., Steele, V.E., Mehta, M.U., Temeck, J.W., Schmidt, W.J., Burke, G., Greenwald, P. and Temple, R.J. (1994) Guidance for development of chemopreventive agents. J. Cell. Biochem. Suppl. 20: 25-31.
  • Lipkin, M. (1994) Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in Phase II clinical trials. J. Cell. Biochem. 19: 94-98.
  • Lubet, R.A., Steele, V.E., Casebolt, T.L., Eto, I., Kelloff, G.J. and Grubbs, C.J. (1994) Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15: 2775-2780.
  • Mitchell, M.F., Hittelman, W.N., Hong, W.K., Lotan, R. and Schottenfeld, D. (1994) The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers. Cancer Epidemiol. Biomark. Prev. 3: 619-626.
  • Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. (1994) Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res. 14: 5-11.
  • Moon, R.C., Rao, K.V.N., Detrisac, C.J., Kelloff, G.J., Steele, V.E. and Doody, L.A. (1994) Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int. J. Oncol. 4: 661-667.
  • Moon, R.C., Steele, V.E., Kelloff, G.J., Thomas, C.F., Detrisac, C.J., Mehta, R.G. and Lubet, R.A. (1994) Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: Toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res. 14: 889-893.
  • Pereira, M.A., Barnes, L.H., Rassman, V.L., Kelloff, G.J. and Steele, V.E. (1994) Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049-1054.
  • Shamon, L.A., Chen, C., Mehta, R.G., Steele, V., Moon, R.C. and Pezzuto, J.M. (1994) A correlative approach for the identification of antimutagens that demonstrate chemopreventive activity. Anticancer Res. 14: 1775-1778.
  • Sharma, S., Stutzman, J.D., Kelloff, G.J. and Steele, V.E. (1994) Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 54: 5848-5855.
  • Singh, J., Kulkarni, N., Kelloff, G. and Reddy, B.S. (1994) Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 15: 1317-1323.
  • Steele, V.E., Moon, R.C., Lubet, R.A., Grubbs, C.J., Reddy, B.S., Wargovich, M., McCormick, D.L., Pereira, M.A., Crowell, J.A., Bagheri, D., Sigman, C.C., Boone, C.W. and Kelloff, G.J. (1994) Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention testing program. J. Cell. Biochem. Suppl. 20: 32-54.
  • Waterhouse, D.M. and Brenner, D. (1994) Aspirin, NSAIDs, and risk reduction of colorectal cancer. The problem is translation. Arch. Intern. Med. 154: 366-368.

1993

  • Boone, C.W. and Kelloff, G.J. (eds.) (1993) Chemoprevention of Breast Cancer: Surrogate Endpoints and Agents in Short-Term Clinical Trials, J. Cell. Biochem. (Suppl. 17G), New York, NY: Wiley-Liss.
  • Boone, C.W. and Kelloff, G.J. (1993) Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer prevention. J. Cell. Biochem. 17 (Suppl. F): 37-48.
  • Boone, C.W. and Kelloff, G.J. (1993) Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J. Cell. Biochem. 17 (Suppl. G): 14-25.
  • Boone, C.W., Kelloff, G.J. and Steele, V.E. (1993) Histopathology of human intraepithelial neoplasia with implications for chemoprevention strategy. Basic Life Sci. 61: 291-300.
  • Creaven, P.J., Pendyala, L. and Petrelli, N.J. (1993) Evaluation of -difluoromethylornithine as a potential chemopreventive agent: Tolerance to daily oral administration in humans. Cancer Epidemiol. Biomark. Prev. 2: 243-247.
  • Dhingra, K., Vogel, V., Sneige, N., Sahin, A., Aldaz, M., Hortobagyi, G.N. and Hittelman, W. (1993) Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. J. Cell. Biochem. 17G: 37-43.
  • Freedman, L.S., Midthune, D.N., Brown, C.C., Steele, V. and Kelloff, G.J. (1993) Statistical analysis of animal cancer chemoprevention experiments. Biometrics 49: 259-268.
  • Greenwald, P. and Kelloff, G.J. (1993) The chemoprevention of cancer. In: General Motors Research Foundation, Accomplishments in Cancer Research 1992, Philadelphia, PA: J.B. Lippincott Co., pp. 242-265.
  • Greenwald, P., Kelloff, G., Kalagher, S. and McDonald, S. (1993) Research studies on chemoprevention of esophageal cancer at the United States National Cancer Institute. Endoscopy 25: 617-626.
  • Grubbs, C.J., Juliana, M.M., Eto, I., Casebolt, T., Whitaker, L.M., Canfield, G.J., Manczak, M., Steele, V.E. and Kelloff, G.J. (1993) Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res. 13: 33-36.
  • Kelloff, G.J., Boone, C.W., Malone, W.F. and Steele, V. (1993) Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. Basic Life Sci. 61: 373-386.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Crowell, J.A., Lubet, R., Doody, L.A. and Greenwald, P. (1993) Development of breast cancer chemopreventive drugs. J. Cell. Biochem. 17 (Suppl. G): 2-13.
  • Kelloff, G.J., Boone, C.W., Steele, V.E., Perloff, M., Crowell, J. and Doody, L.A. (1993) Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J. Cell. Biochem. 17 (Suppl. F): 2-17.
  • Love, R.R, Carbone, P.P, Verma, A.K., Gilmore, D., Carey, P., Tutsch, K.D., Pomplun, M. and Wilding, G. (1993) Randomized Phase I chemoprevention dose-seeking study of -difluoromethylornithine. J. Natl. Cancer Inst. 85: 732-737.
  • Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. (1993) Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 14: 1487-1489.
  • Pendyala, L., Creaven, P.J. and Porter, C.W. (1993) Urinary and erythrocyte polyamines during the evaluation of oral -difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer Epidemiol. Biomark. Prev. 2: 235-241.
  • Rao, C.V., Rivenson, A., Katiwalla, M., Kelloff, G.J. and Reddy, B.S. (1993) Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res. 53: 2502-2506.
  • Reddy, B.S., Rao, C.V., Rivenson, A. and Kelloff, G. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497.
  • Reddy, B.S., Rao, C.V., Rivenson, A. and Kelloff, G. (1993) Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res. 53: 3493-3498.
  • Ruffin, M.T., IV, August, D.A., Kelloff, G.J., Boone, C.W., Weber, B.L. and Brenner, D.E. (1993) Selection criteria for breast cancer chemoprevention. J. Cell. Biochem. 17 (Suppl. G): 234-241.
  • Schantz, S.P., Hong, W.K., Boone, C.W. and Kelloff, G.J. (eds.) (1993) Chemoprevention of Premalignant Lesions of the Upper Aerodigestive Tract, J. Cell. Biochem. (Suppl. 17F), New York, NY: Wiley-Liss.
  • Schantz, S.P., Hong, W.K., Boone, C.W. and Kelloff, G.J. (1993) Strategy for design of clinical trials of chemopreventive agents. J. Cell. Biochem. 17 (Suppl. F): 299-300.
  • Singh, J., Kelloff, G. and Reddy, B.S. (1993) Intermediate biomarkers of colon cancer: Modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis 14: 699-704.
  • Steele, V.E., Boone, C.W. and Kelloff, G.J. (1993) Strategies for development of chemoprevention agents. Comm. Toxicol. 4: 427-436.

1992

  • Boone, C.W., Kelloff, G.J. and Steele, V.E. (1992) Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res. 52: 1651-1659.
  • Boone, C.W., Kelloff, G.J. and Steele, V.E. (1992) The natural history of intraepithelial neoplasia: Relevance to the search for biomarkers. J. Cell. Biochem. 16 (Suppl. G): 23-26.
  • Boone, C.W., Kelloff, G.J. and Steele, V.E. (1992) Histopathology of human intraepithelial neoplasia with implications for chemoprevention strategy. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention, Boca Raton, FL: CRC Press, pp. 57-67.
  • Boone, C.W., Steele, V.E. and Kelloff, G.J. (1992) Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat. Res. 267: 251-255.
  • Bostwick, D.G., Scardino, P.T., Kelloff, G.J. and Boone, C.W. (eds.) (1992) Chemoprevention of Premalignant and Early Malignant Lesions of the Prostate, J. Cell. Biochem. (Suppl. 16H), New York, NY: Wiley-Liss.
  • Crawford, E.D., Fair, W.R., Kelloff, G.J., Lieber, M.M., Miller, G.J., Scardino, P.T. and DeAntoni, E.P. (1992) Chemoprevention of prostate cancer: Guidelines for possible intervention strategies. J. Cell. Biochem. 16 (Suppl. H): 140-145.
  • Hemstreet, G.P., III, Rao, J.Y., Hurst, R.E., Bonner, R.B., Jones, P.L., Vaidya, A.M., Fradet, Y., Moon, R.C. and Kelloff, G.J. (1992) Intermediate endpoint biomarkers for chemoprevention. J. Cell. Biochem. 16 (Suppl. I): 93-110.
  • Kelloff, G.J., Boone, C.W., Malone, W.F., Steele, V.E. and Doody, L.A. (1992) Introductory remarks: Development of chemopreventive agents for prostate cancer. J. Cell. Biochem. 16 (Suppl. H): 1-8.
  • Kelloff, G.J., Boone, C.W., Malone, W.F. and Steele, V. (1992) Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention, Boca Raton, FL: CRC Press, pp. 41-56.
  • Kelloff, G.J., Boone, C.W., Malone, W.F. and Steele, V.E. (1992) Chemoprevention clinical trials. Mutat. Res. 267: 291-295
  • Kelloff, G.J., Boone, C.W., Malone, W.F., Steele, V.E. and Doody, L.A. (1992) Development of chemopreventive agents for bladder cancer. J. Cell. Biochem. 16 (Suppl. I): 1-12.
  • Kelloff, G.J., Malone, W.F., Boone, C.W., Steele, V.E. and Doody, L.A. (1992) Intermediate biomarkers of precancer and their applications in chemoprevention. J. Cell. Biochem. 16 (Suppl. G): 15-22.
  • Kulkarni, N., Zang, E., Kelloff, G. and Reddy, B.S. (1992) Effect of the chemopreventive agents piroxicam and d,l- -difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis 13: 995-1000.
  • Lipkin, M., Levin, B., Kim, Y.S. and Kelloff, G.J. (eds.) (1992) Intermediate Biomarkers of Precancer and Their Application in Chemoprevention, J. Cell. Biochem. (Suppl. 16G), New York, NY: Wiley-Liss.
  • Malone, W.F., Boone, C.W. and Kelloff, G.J. (1992) Drug development status of four leading chemopreventive agents at the National Cancer Institute. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention, Boca Raton, FL: CRC Press, pp. 597-606.
  • Messing, E.M. and Reznikoff, C.A. (1992) Epidermal growth factor and its receptor: Marker of and targets for chemoprevention of bladder cancer. J. Cell. Biochem. 16I: 56-62.
  • Messing, E.M., Sheinfeld, J., Boone, C.W. and Kelloff, G.J. (eds.) (1992) Chemoprevention of Premalignant and Early Malignant Lesions of the Bladder, J. Cell. Biochem. (Suppl. 16I), New York, NY: Wiley-Liss.
  • Moon, R.C., Detrisac, C.J., Thomas, C.F. and Kelloff, G.J. (1992) Chemoprevention of experimental bladder cancer. J. Cell. Biochem. 16I: 134-138.
  • Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. (1992) Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12: 1147-1154.
  • Moon, R.C., Mehta, R.G. and Detrisac, C.J. (1992) Retinoids as chemopreventive agents for breast cancer. Cancer Detect. Prev. 16: 73-79.
  • Moon, R.C., Rao, K.V.N, Detrisac, C.J. and Kelloff, G.J. (1992) Hamster lung cancer model of carcinogenesis and chemoprevention. Adv. Exp. Med. Biol. 320: 55-61.
  • Moon, R.C., Rao, K.V.N., Detrisac, C.J. and Kelloff, G.J. (1992) Retinoid chemoprevention of lung cancer. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention, Boca Raton, FL: CRC Press, pp. 83-93.
  • Moon, R.C., Rao, K.V.N., Detrisac, C.J. and Kelloff, G.J. (1992) Animal models for chemoprevention of respiratory cancer. J. Natl. Cancer Inst. Monogr. 13: 45-49.
  • Reddy, B.S., Tokumo, K., Kulkarni, N., Aligia, C. and Kelloff, G. (1992) Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019-1023.
  • Sheinfeld, J., Herr, H.W., Boone, C.W., Bostwick, D.G., Clark, L.C., Decensi, A.U., de Vere White, R.W., Farrow, G.M., Fradet, Y., Grossman, H.B., Hemstreet, G.P., III, Kelloff, G.J., Koss, L.P., Logothetis, C.J., Loprinzi, C.L., Melamed, M.R., Prout, G., Jr., Reuter, V., Soloway, M.S., von Eschenbach, A.C. and Whitmore, W.F., Jr. (1992) Intervention strategies for chemoprevention of bladder cancer. J. Cell. Biochem. 16I: 173-174.
  • Singh, J., Kelloff, G. and Reddy, B.S. (1992) Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis. Cancer Epidemiol. Biomark. Prev. 1: 405-411.
  • Steele, V.E., Boone, C.W., Stoner, G.D. and Kelloff, G.J. (eds.) (1992) Cellular and Molecular Targets for Chemoprevention, Boca Raton, FL: CRC Press.
  • Wargovich, M.J., Harris, C., Chen, C.-D., Palmer, C., Steele, V.E. and Kelloff, G.J. (1992) Growth kinetics and chemoprevention of aberrant crypts in the rat colon. J Cell. Biochem. 16 (Suppl. G): 51-54.
  • Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) (1992) Cancer Chemoprevention, Boca Raton, FL: CRC Press.

1991

  • Alexandrov, V.A., Bespalov, V.G., Boone, C.W., Kelloff, G.J. and Malone, W.F. (1991) Study of postnatal effects of chemopreventive agents on offspring of ethylnitrosourea-induced transplacental carcinogenesis in rats. I. Influence of retinol acetate, -tocopherol acetate, thiamine chloride, sodium selenite, and -difluoromethylornithine. Cancer Lett. 60: 177-184.
  • Boone, C.W., Kelloff, G.J. and Steele, V. (1991) Histopathology of the premalignant process. Cancer Bull. 43: 481-484.
  • Hurst, R.E., Rhodes, S.W., Petrone, R., Bass, R.A., Hemstreet, G.P., Detrisac, C.J., Thomas, C.F., Moon, R.C. and Kelloff, G.J. (1991) Quantitative biochemical markers of DNA hyperploidy as end-point indicators in chemical risk assessment and chemoprevention studies. J. Biol. Mon. 1: 5-18.
  • Lipkin, M., Newmark, H.L. and Kelloff, G.J. (eds.) (1991) Calcium, Vitamin D, and Prevention of Colon Cancer, Boca Raton, FL: CRC Press.
  • Lipkin, M., Newmark, H., Boone, C.W. and Kelloff, G.J. (1991) Calcium, vitamin D, and colon cancer. Cancer Res. 51: 3069-3700.
  • Malone, W.F., Kelloff, G.J. and Boone, C.W. (1991) Ongoing preclinical and initial clinical studies in chemoprevention. In: Pastorino, U. and Hong, W.K. (eds.) Chemoimmuno Prevention of Cancer, Stuttgart, Germany: Thieme, pp. 111-123.
  • Mehta, R.G. and Moon, R.C. (1991) Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res. 11: 593-596.
  • Mehta, R.G., Barua, A.B., Olson, J.A. and Moon, R.C. (1991) Effects of retinoid glucuronides on mammary gland development in organ culture. Oncology 48: 505-509.
  • Mehta, R.G., Steele, V., Kelloff, G.J. and Moon, R.C. (1991) Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res. 11: 587-592.
  • Rao, C.V., Nayini, J. and Reddy, B.S. (1991) Effect of oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] on azoxymethane-induced biochemical changes related to early colon carcinogenesis in male F344 rats. Proc. Soc. Exp. Biol. Med. 197: 77-84.
  • Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G. and Reddy, B.S. (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, -difluoromethylornithine, 16 -fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51: 4528-4534.
  • Rao, C.V., Tokomo, K., Kelloff, G. and Reddy, B.S. (1991) Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 12: 1051-1055.
  • Ratko, T.A., Detrisac, C.J., Mehta, R.G., Kelloff, G.J. and Moon, R.C. (1991) Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res. 51: 481-486.
  • Rhodes, S.W., Hurst, R.E., Rollins, S.A., Jones, P.L., Hemstreet, G.P., Moon, R.C., Thomas, C.F., Detrisac, C.J. and Kelloff, G.J. (1991) DNA ploidy and p21 protein levels in tissue sections as end-point markers in animal carcinogenesis trials. Biol. Monit. 1: 61-73.

1990

  • Boone, C.W., Kelloff, G.J. and Malone, W.F. (1990) Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res. 50: 2-9.
  • Greenwald, P., Nixon, D.W., Malone, W.F., Kelloff, G.J., Stern, H.R. and Witkin, K.M. (1990) Concepts in cancer chemoprevention research. Cancer 65: 1483-1490.
  • Kelloff, G.J., Malone, W.F., Boone, C.W., Sigman, C.C. and Fay, J.R. (1990) Progress in applied chemoprevention research. Semin. Oncol. 17: 438-455.
  • Ratko, T.A., Detrisac, C.J., Rao, K.V.N., Thomas, C.F., Kelloff, G.J. and Moon, R.C. (1990) Interspecies analysis of the chemopreventive efficacy of dietary -difluoromethylornithine. Anticancer Res. 10: 67-72.
  • Reddy, B.S., Nayini, J., Tokumo, K., Rigotty, J., Zang, E. and Kelloff, G. (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug, with D,L- -difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 50: 2562-2568.
  • Steele, V.E., Kelloff, G.J., Wilkinson, B.P. and Arnold, J.T. (1990) Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents. Cancer Res. 50: 2068-2074.

1989

  • Bagheri, D., Doeltz, M.K., Fay, J.R., Helmes, C.T., Monasmith, L.A. and Sigman, C.C. (1989) Database of inhibitors of carcinogenesis. J. Environ. Sci. Health 6(3).
  • Greenwald, P., Cullen, J.W., Kelloff, G. and Pierson, H.F. (1989) Chemoprevention of lung cancer: Problems and progress. Chest 96 (Suppl. 1): 14s-17s.
  • Malone, W.F., Kelloff, G.J., Boone, C. and Nixon, D.W. (1989) Chemoprevention and modern cancer prevention. Prev. Med. 18: 553-561.
  • Malone, W.F. and Kelloff, G.J. (1989) Chemoprevention strategies utilizing combinations of inhibitors of carcinogenesis [editorial]. J. Natl. Cancer Inst. 81: 824.
  • Moon, R.C., Pritchard, J.F., Mehta, R.G., Nomides, C.T., Thomas, C.F. and Dinger, N.M. (1989) Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 10: 1645-1649.
  • Ratko, T.A., Detrisac, C.J., Dinger, N.M., Thomas, C.F., Kelloff, G.J. and Moon, R.C. (1989) Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49: 4472-4476.

1988

  • Malone, W.F., Kelloff, G.J., Pierson, H. and Greenwald, P. (1987) Chemoprevention of bladder cancer. Cancer 60 (Suppl. 3): 650-657.

1987

  • Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47: 5340-5346.

1986

  • Dimitrov, N.V., Boone, C.W., Hay, M.B., Whetter, P., Pins, M., Kelloff, G.J. and Malone, W. (1986) Plasma -carotene levelsókinetic patterns during administration of various doses of -carotene. J. Nutr. Growth Cancer 3: 227-237.

1985

  • DeWys, W.D., Malone, W.F., Sestili, M.A., Kelloff, G.J. and Boone, C.W. (1985) The chemoprevention program of the National Cancer Institute. In: Meyskens, F.L. and Prasad, K.N. (eds.) Vitamins and Cancer. Human Cancer Prevention by Vitamins and Micronutrients, Clifton, NJ: Humana Press, pp. 301-310.
  • Micozzi, M.S., Boone, C.W., Kelloff, G.J., Tangrea, J.A., Helzlsouer, K.J. and Taylor, P.R. (1985) Chemoprevention of cancer: Implications for clinical pharmacology. J. Clin. Pharmacol. 25: 164-175.

Back to top